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ABSTRACT 
CROSS-SECTIONAL AND LONGITUDINAL EFFECTS OF GLYCEMIC STATUS 
ON BODY COMPOSITION, BONE, AND LIPID PROFILE IN MEN AGED 20 TO 66 
YEARS: A POPULATION-BASED STUDY 
KHALEAL ALMUSAYLIM 
2019 
        Pre-diabetes and type 2 diabetes (T2D) are significant public health challenges in the 
United States. Pre-diabetes and T2D are a multi-factorial disease characterized by genetic 
or environmental factors or a combination of both.  There has been an upward trend over 
time in the prevalence of both pre-diabetes and T2D. Few epidemiological studies exist 
regarding the effect of baseline glycemic status on changes in body composition, bone 
health, and lipid profiles. To fill this critical gap, the purpose of this research was to 
examine both cross-sectional and longitudinal changes in glycemic status with changes in 
body composition, bone mass and density, and lipid profile and cardiovascular risk ratios 
in men aged 20 to 66 years.  
       This dissertation uses data from the South Dakota Rural Bone Health Study, a 
population-based longitudinal study designed to investigate the impact of lifestyle factors 
on bone and body composition. Findings from this study provide insight into the adverse 
effect of changes in glycemic status on total and regional body composition and bone 
health. Creating prevention strategies targeted at individuals affected by, or at risk of, 
pre-diabetes and T2D, such as promoting a healthy diet, physical activity, and weight loss 
may reverse the unfavorable effects of pre-diabetes and T2D.
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  CHAPTER 1: Introduction   
 
Pre-diabetes 
Pre-diabetes is a hyperglycemic state, which a blood glucose concentration is 
greater than normal and lower than type 2 diabetes (T2D) thresholds. Pre-diabetes occurs 
in response to defects in insulin sensitivity and secretion as a result of impaired β-cell 
function and insulin resistance [1]. The current diagnostic criteria from the American 
Diabetes Association (ADA) define pre-diabetes as impaired fasting blood glucose of 100 
to 125 mg/dL, or impaired glucose tolerance of 140 to 199 mg/dL, or hemoglobin A1c 
(HbA1c) of 5.7 to 6.4% [2]. Different criteria used to diagnose pre-diabetes result in 
heterogeneity within subjects. Individuals with impaired fasting glucose seem to have 
moderate insulin resistance in the liver and adipose tissue, impaired first-phase insulin 
secretion in the pancreas, and normal or nearly normal insulin sensitivity in the muscle, 
whereas those with impaired glucose tolerance seem to have moderate to severe muscle 
insulin resistance, insulin secretory defect, and nearly normal hepatic insulin sensitivity  
[3,4].  
The number of adults with pre-diabetes the United States (US) increased from 79 
million in 2010 to 84.1 million in 2015 (20% annually) [5,6]. The prevalence of pre-
diabetes in the US among adults aged ≥ 18 years was 33.9% in 2015. Only11.6% of pre-
diabetics were aware of their condition. The prevalence of pre-diabetes varies across age 
and sex. Men (36.9%) and older adults aged ≥ 65 years (48.3%) have higher pre-diabetes 
than women (31.1%) and young (23.7%) and middle-aged (40.9%) adults [6]. Pre-
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diabetes is associated with cardiovascular disease [7,8] and coronary heart disease [9]. 
Pre-diabetes places an economic burden on diagnosed individuals and health care 
services. The total average medical cost per case was $510 per year, and the total medical 
and nonmedical costs were $43, 910 million in 2012 [10].  
The ADA recommends lifestyle modifications, including 7% loss of initial body 
weight, caloric restriction, and performing 150 minutes moderate physical activity per 
week, as a key prevention strategy for T2D. Achievement and maintenance of lifestyle 
modifications play a pivotal role in stopping the conversion from pre-diabetes to T2D 
[11]. The pre-diabetic state may last for several years ranging from one year to six years 
before reverting to normoglycemia or progressing to T2D. In the US, intervention studies 
reported that lifestyle changes result in 40% reversion from pre-diabetes to 
normoglycemia over three years [12]. Conversion from pre-diabetes to T2D was 31.5% 
within three years in adults without lifestyle modifications [13].  
Type 2 Diabetes  
T2D has become a major concern in the US and is characterized by 
hyperglycemia due to defects of insulin secretion and action. T2D is caused by a 
combination of insulin resistance and β-cell dysfunction [14]. Accumulation of ectopic 
fat in the liver and muscle as a consequence of greater intake of total energy than energy 
expenditure contributes to insulin resistance in response to a reduction in fat oxidation in 
mitochondria [15]. Fat deposition in the pancreas may lead to the impairment in β-cell 
function [16]. The current ADA diagnostic criteria for T2D are as follows: impaired 
fasting blood glucose ≥ 126 mg/d, or 2-h plasma glucose ≥ 200 mg/dL, or HbA1c ≥ 
6.5%, or random plasma glucose ≥ 200 mg/dL [2]. The age-adjusted prevalence of T2D 
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among US adults aged ≥ 20 years was 8.2% in 2016-2017. The prevalence of T2D has 
increased due to the aging of the US population and increased rates of obesity. In 2016-
2017, the prevalence of T2D was 11.1% and 18.2% of American adults aged 45 to 64 
years and 65 years, respectively. The 2016-2017 National Health Interview Survey 
reported 6.7% of overweight and 14.1% of obese adults had T2D [17].  
T2D adults suffer microvascular and macrovascular complications [18] that are a 
major cause of morbidity and mortality [19]. T2D imposes a large financial burden on 
patients, quality of life, and healthcare system costing millions of dollars. In 2007, the US 
national economic burden of T2D was estimated at $9,677 per case, $105.7 million 
dollars for medical cost and $53.8 million dollars for nonmedical cost [20]. T2D 
management in each care setting is crucial to reducing the economic burden. Lifestyle 
intervention studies have consistently reported that changes in lifestyle behaviors (weight 
reduction, healthy eating plus increasing physical activity) are accompanied by a 58% 
risk reduction in T2D [12,21]. These intervention studies provide clear empirical 
evidence of the role of achieving health behaviors goals in the prevention of T2D.  
Dysglycemia and Body Composition 
Chronic inflammation, oxidative stress, and abnormality of lipid metabolism 
promote insulin resistance [22,23] that precedes the onset of pre-diabetes and 
T2D.  Insulin resistance is identified as a risk factor affecting total and regional body 
composition in middle-aged and older men [24,25]. Therefore, alteration in total body 
(TB) composition and its distribution can occur early in the upper and lower extremities 
before the development of dysglycemia (pre-diabetes or T2D). Insulin-resistant men are 
more likely to lose TB and appendicular lean mass (LM) [24,25] and less likely to gain 
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TB and trunk fat mass (FM) [25]. Disturbance in the balance between anabolism and 
catabolism of muscle protein and increased rates of lipolysis contribute to skeletal muscle 
loss and decreased fat gain in insulin-resistant men [25,26]. Since insulin resistance 
directly affects skeletal muscle and adipose tissue, alterations in body composition is 
further augmented by dysglycemia.  
The evidence, however, to support the association of glycemic status with total 
and regional FM and LM remains inconclusive. Case-control and cross-sectional studies 
of middle-aged and older adults have shown positive, negative or no association of 
glycemic status with absolute or percent TB and regional FM and LM as presented in 
Tables 1.1 and 1.2 [27-34]. A possible explanation of greater FM of upper and lower 
limbs in pre-diabetic and T2D individuals is an accumulation of intra-abdominal and 
intermuscular adipose tissue. T2D subjects had greater visceral and intermuscular adipose 
tissues than normoglycemic stbjucts, suggesting that subjects with T2D had a larger 
porportion of visceral and intermuscular adipose tiusses to TB FM. Visceral adipose 
tissue and adipose tissue interspread wihin skeletal muscle lead to more accumlation of 
ectopic fat [35,36].   
Only three longitudinal studies have examined the association of baseline 
glycemic status with absolute changes in TB FM and its compartments and these studies 
have shown mixed findings (Table 1.1) [37-40]. Pre-diabetic young adults slightly gained 
TB FM over time compared to their normoglycemic counterparts [37]. No changes or 
small increases in TB and trunk FM were seen in middle-aged and older adults with T2D 
[38-40]. The underlying mechanism for lower rates of TB and trunk FM gain in 
dysglycemic individuals may be due to greater rises in energy expenditure and fat 
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oxidation leading to attenuation of FM gain [37].  Prospective cohort studies have 
produced contradictory findings with respect to the relationship of baseline glycemic 
status to changes in TB LM and its distribution (Table 1.2) [37-42]. Dysglycemia appears 
to accelerate the loss of absolute and percent TB, appendicular, and leg LM [39-41] 
through various mechanistic pathways including insulin resistance, hyperglycemia, 
dysfunctional mitochondria, chronic inflammation, oxidative stress, and fat infiltration 
into the muscle [43].   
6 
 
Table 1.1. Baseline and changes in total and regional fat mass (FM) by glycemic status. 
 
Study name 
Participants 
(Follow-up 
time) 
Diagnosis of 
dysglycemia Covariates 
FM 
measures Findings 
Case-control studies 
Community-
dwelling 
cohort [27] 
30 Swedish men 
aged 48-49 years, 
17 NG and 13 
T2D 
OGTT Matched by 
age, height, and 
BMI 
TB FM 
Trunk FM 
No difference between groups  
Greater in T2D group than in NG group 
Look AHEAD 
trial [28] 
102 US adults 
55-60 years, 35 
Non-T2D and 67 
T2D 
 FBG, 
OGTT, self-
reported, and 
drug use 
Age, sex, 
ethnicity, site, 
height, and TB 
FM for trunk 
and leg FM 
TB FM 
Trunk FM 
 
Leg FM 
No difference between groups 
Greater in T2D group than in Non-T2D 
group 
Lower in T2D group than in Non-T2D 
group 
Community-
dwelling 
cohort [29] 
92 Dutch men 
aged 69-72 years, 
32 NG and 60 
T2D 
 OGTT Age, BMI, 
FBG, HDL, 
BCAA, protein 
intake, and 
physical activity 
TB FM No difference between groups 
 
Cross-sectional studies 
Outpatient 
clinic for 
GMD [30] 
142 Polish men 
aged 62-70 years, 
58 NG and 84 
pre-diabetic 
FBG, OGTT, 
and HbA1c 
 TB FM 
 
Trunk FM 
Leg FM 
Greater in pre-diabetic group than in NG 
group 
No difference between groups  
No difference between groups  
 
NHANES [31] 1781 US men 
aged 51-78 years, 
1223 NG and 
558 pre-diabetic 
FBG Age, BMI, 
ethnicity, 
alcohol intake, 
smoking, and 
physical activity 
TB FM 
 
Trunk FM 
 
Appendicular 
FM 
Greater in pre-diabetic group than in NG 
group 
Greater in pre-diabetic group than in NG 
group 
No difference among groups 
Look AHEAD 
trial [32] 
1557 US adults 
aged 55-59 years, 
242 NG and 
1315 T2D 
FBG, OGTT, 
self-reported, 
and drug use 
Age, sex, 
ethnicity, site, 
height, and 
weight for TB 
FM  
Age, sex, 
ethnicity, site, 
height, and TB 
FM for trunk 
and leg FM  
TB FM 
Trunk FM 
Leg FM 
Lower in T2D group than in NG group 
Greater in T2D group than in NG group 
Lower in T2D group than in NG group 
KSOS [33] 370 Korean men 
aged 48-69 years, 
152 NG and 218 
T2D 
FBG and 
HbA1c 
Age, BMI, 
physical 
activity, 
smoking, 
alcohol intake, 
antihypertensive 
agent, lipid 
lowering agent, 
systolic and 
diastolic blood 
pressure, TC, 
HDL, TG, and 
FBG.  
TB FM 
 
Greater in T2D group than in NG group 
NHANES [31] 1353 men 
aged51-75 years, 
1223 NG and 
130 T2D 
FBG Age, BMI, 
ethnicity, 
alcohol intake, 
smoking, and 
physical activity 
TB FM 
Trunk FM 
Appendicular 
FM 
No difference between groups  
Greater in T2D group than in NG group 
No difference between groups 
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Table 1.1. Baseline and changes in total and regional fat mass (FM) by glycemic status – 
continued. 
 
Study name 
Participants 
(Follow-up 
time) 
Diagnosis of 
dysglycemia Covariates 
FM 
measures Findings 
Prospective studies 
Respiratory 
chamber study 
[37] 
122 Native 
American adults 
aged 20-31, 101 
NG and 21 pre-
diabetic  
(Over 5 years) 
FBG and 
OGTT 
Age, sex, and 
baseline body 
weight. 
TB FM Slight gain in pre-diabetic group in contrast to NG 
group 
Health ABC 
Study [38] 
2449 US adults 
aged 71-77 years, 
2047 NG and 
402 T2D  
(Over 6 years) 
FBG, OGTT, 
HbA1c, self-
reported, and 
drug use 
Age, sex, 
ethnicity, site, 
BMI, weight 
loss intention, 
and change in 
body weight. 
TB FM 
Trunk FM 
Appendic
ular FM 
No difference between groups  
Slight gain in T2D group in contrast to NG group 
No difference between groups  
 
Randomized trial studies 
Look AHEAD 
trial [39,40] 
422 US men 
aged 52-66 years, 
220 T2D in DSE 
and 202 T2D in 
ILI  
(Over 8 years) 
FBG, OGTT, 
self-reported, 
and drug use 
Age, clinic, 
ethnicity, 
HbA1c, time, 
and baseline 
body 
composition 
measure 
TB FM 
Trunk FM 
Leg FM 
Slight gain from baseline within the DSE group 
No change from baseline within the DSE group 
No change from baseline within the DSE group 
Abrreviation: GMD, glucose metabolism disorder; NHANES, the National Health and Nutrition Examination Survey; KSOS, the 
Korean Sarcopenic Obesity Study; Health ABC Study, the Health, Aging, and Body composition Study; NG, normoglycemic, T2D, 
type 2 diabetic; DSE, diabetes support and education; ILI, intensive lifestyle intervention; OGTT, oral glucose tolerance test; FBG, 
fasting blood glucose; HbA1c, hemoglobin A1c; BMI, body mass index; TB FM, total body fat mass; HDL, high-density lipoprotein 
cholesterol; BCAA, branched-chain amino acid; TC, total cholesterol; and TG, triglyceride.    
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Table 1.2. Baseline and changes in total and regional lean mass (LM) by glycemic status. 
 
Study name 
Participants 
(Follow-up 
time) 
Diagnosis of 
dysglycemia Covariates 
LM 
measures Findings 
Case-control studies 
Look AHEAD 
trial [28] 
102 US adults 
aged 47-67 years, 
35 Non-T2D and 
67 T2D 
FBG, OGTT, 
self-reported, 
and drug use 
Age, sex, 
ethnicity, site, 
height, and TB 
FM except for 
TB FM as an 
outcome 
measure 
TB LM 
 
No difference between groups 
 
Community-
dwelling 
cohort [29] 
92 Dutch men 
aged 69-72 years, 
32 NG and 60 
T2D 
OGTT Age, BMI, 
FBG, HDL, 
BCAA, protein 
intake, and 
physical activity 
TB LM 
Appendicul
ar LM 
No difference between groups 
Greater in NG group than in pre-diabetic group 
 
Cross-sectional studies 
NHANES [34] 2529 US men 
aged 61-67 years, 
1283 NG and 
1246 pre-diabetic 
HbA1c Age, height, 
ethnicity, 
education, 
smoking, 
physical 
activity, CRP, 
CHD, PAD, 
arthritis, 
neuropathy, hip 
fracture, lower- 
limb 
amputation, 
cancer, and 
COPD. 
%TB LM 
%Trunk 
LM 
%Appendic
ular LM 
Lower in pre-diabetic group than in NG group 
Lower in pre-diabetic group than in NG group 
 
Lower in pre-diabetic group than in NG group 
 
Outpatient 
clinic for 
GMD [30] 
142 Polish men 
aged 62-70 years, 
58 NG and 84 
pre-diabetic 
FBG, OGTT, 
and HbA1c 
 TB LM 
Trunk LM 
Leg LM 
Greater in NG group than in pre-diabetic group 
No difference between groups  
No difference between groups  
 
NHANES [31] 1781 US men 
aged 51-78 years, 
1223 NG and 
558 pre-diabetic 
FBG Age, BMI, 
ethnicity, 
alcohol intake, 
smoking, and 
physical activity 
TB LM 
Trunk LM 
Appendicul
ar LM 
No difference between groups  
No difference between groups  
No difference among groups 
Look AHEAD 
trial [32] 
1557 US adults 
aged 45-76 years, 
242 NG and 
1315 T2D 
 FBG, 
OGTT, self-
reported, and 
drug use 
Age, sex, 
ethnicity, site, 
height, and 
weight for TB 
LM  
Age, sex, 
ethnicity, site, 
height, and TB 
LM for trunk 
and leg LM 
TB LM 
Trunk LM 
Leg LM 
Greater in T2D group than in NG group 
Greater in T2D group than in NG group 
Lower in T2D group than in NG group 
KSOS [33] 370 Korean men 
aged 48-69, 152 
NG and 218 T2D 
FBG and 
HbA1c 
Age, BMI, 
physical 
activity, 
smoking, 
alcohol intake, 
antihypertensive 
agent, lipid 
lowering agent, 
systolic and 
diastolic blood 
pressure, TC, 
HDL, TG, and 
FBG. 
TB LM 
Appendicul
ar LM 
 
Lower in group T2D than in NG group 
No difference between groups 
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Table 1.2. Baseline and changes in total and regional lean mass (LM) by glycemic status 
– continued. 
 
Study name 
Participants 
(Follow-up 
time) 
Diagnosis of 
dysglycemia Covariates 
LM 
measures Findings 
NHANES [34] 1418 US men 
aged 61-65 years, 
1283 NG and 
135 T2D 
Self-reported 
and HbA1c 
Age, height, 
ethnicity, 
education, 
smoking, 
physical 
activity, CRP, 
CHD, PAD, 
arthritis, 
neuropathy, hip 
fracture, lower- 
limb 
amputation, 
cancer, and 
COPD.  
%TB LM 
%Trunk 
LM 
%Appendic
ular LM 
Lower in T2D group than in NG group 
Lower in T2D group than in NG group 
 
Lower in T2D group than in NG group 
 
NHANES [31] 1353 US men 
aged 51-75 years, 
1223 NG and 
130 T2D 
FBG Age, BMI, 
ethnicity, 
alcohol intake, 
smoking, and 
physical activity 
TB LM 
Trunk LM 
Appendicul
ar LM 
No difference among groups  
No difference among groups  
No difference among groups 
Prospective studies 
MrOS [41] 3256 US men 
aged 67-78 years, 
1853 NG and 
1403 pre-diabetic  
(Over 4.6 years) 
FBG, self-
reported, and 
drug use 
Age, ethnicity, 
clinic site, self-
rated health, 
cardiac disease, 
hypertension, 
dyslipidemia, 
education, 
physical 
activity, and 
baseline TB FM 
for TB LM as 
an outcome 
measure and TB 
LM for 
appendicular 
LM as an 
outcome 
measure 
%TB LM 
%Appendic
ular LM 
No difference among groups  
Slight decline in pre-diabetic group in contrast to 
NG group 
Respiratory 
chamber study 
[37] 
122 Native 
American adults 
aged 20-31years, 
101 NG and 21 
pre-diabetic  
(Over 5 years) 
FBG and 
OGTT 
Age, sex, and 
baseline body 
weight. 
TB LM No difference between groups  
 
Health ABC 
Study [38] 
2449 US adults 
aged 71-77 years, 
2047 NG and 
402 T2D  
(Over 6 years) 
FBG, OGTT, 
HbA1c, self-
reported, and 
drug use 
Age, sex, 
ethnicity, site, 
BMI, weight 
loss intention, 
and change in 
body weight. 
TB LM 
Trunk LM 
Appendicul
ar LM 
No difference between groups  
Slight gain in T2D group in contrast to NG group  
No difference between groups  
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Table 1.2. Baseline and changes in total and regional lean mass (LM) by glycemic status 
– continued. 
 
Study name 
Participants 
(Follow-up 
time) 
Diagnosis of 
dysglycemia Covariates 
LM 
measures Findings 
MrOS [41]  1964 US men 
aged 67-78 years, 
1853 NG and 
111 T2D* 
(3.5 years) 
FBG, self-
reported, and 
drug use 
Age, ethnicity, 
clinic site, self-
rated health, 
cardiac disease, 
hypertension, 
dyslipidemia, 
education, 
physical 
activity, and 
baseline TB FM 
for TB LM as 
an outcome 
measure and TB 
LM for 
appendicular 
LM as an 
outcome 
measure  
%TB LM 
%Appendic
ular LM 
Rapid decline in T2D group in contrast to NG group 
Rapid decline in T2D group in contrast to NG group 
BLSA [42] 984 US adults 
aged 44-79 years, 
663 Non-T2D 
and 321 T2D 
(7.5 years) 
HbA1c Age, sex, 
ethnicity, time, 
height, weight, 
physical 
activity, and 
nerve 
conduction 
velocity. 
TB LM 
Leg LM 
No difference between groups  
No difference between groups 
Randomized trial studies 
Look AHEAD 
trial [39,40] 
422 T2D US men 
aged 52-66 years, 
220 T2D in DSE 
and 202 T2D in 
ILI 
(Over 8 years) 
FBG, OGTT, 
self-reported, 
and drug use 
Age, clinic, 
ethnicity, 
HbA1c, time, 
and baseline 
body 
composition 
measure 
TB LM 
Trunk LM 
Leg LM 
Slight decline from baseline within the DSE group  
Slight decline from baseline within the DSE group 
Slight decline from baseline within the DSE group 
Abrreviation: GMD, glucose metabolism disorder; NHANES, the National Health and Nutrition Examination Survey; KSOS, the 
Korean Sarcopenic Obesity Study; Health ABC Study, the Health, Aging, and Body composition Study; NG, normoglycemic, T2D, 
type 2 diabetic; DSE, Abrreviation: GMD, glucose metabolism disorder; NHANES, the National Health and Nutrition Examination 
Survey; KSOS, the Korean Sarcopenic Obesity Study; Health ABC Study, the Health, Aging, and Body composition Study; NG, 
normoglycemic, T2D, type 2 diabetic; DSE, diabetes support and education; ILI, intensive lifestyle intervention; OGTT, oral glucose 
tolerance test; FBG, fasting blood glucose; HbA1c, hemoglobin A1C; BMI, body mass index; TB LM, total body lean mass; HDL, 
high-density lipoprotein cholesterol; BCAA, branched-chain amino acid; TC, total cholesterol; TG, triglyceride; CRP, C-reactive 
protein; CHD, coronary heart disease; PAD, peripheral arterial disease; and COPD, chronic obstructive pulmonary disease .    
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All studies have failed to use large sample sizes except for three cross-sectional 
[31,32,34] and longitudinal [38,41,42] studies as shown in Tables 1 and 2. This may 
explain limited power to detect differences in primary outcomes among glycemic groups. 
Another limitation is that the study populations included middle-aged and older subjects 
[28-34,38-42] in which findings cannot be generalized to their younger counterparts. A 
further limitation is related to how the data were analyzed. One cross-sectional study 
adjusted for TB FM and LM when testing the relationship between glycemic status and 
regional body composition [28]. Two of the longitudinal studies adjusted for baseline 
body composition measures when examing the relation of glycemic status to changes in 
TB composition and its distribution [39,40]. The remaining studies controlled for body 
mass index (BMI) [27,29,31,33,38] or body weight [32,37,38,42] and HbA1c [39] or 
fasting blood glucose (FBG) [29,33] that could lead to an over-adjustment due to its high 
correlation with body composition and glycemic measures.  Sample size, adjustment for a 
various covariates, and diagnosis of dysglycemia may account for the inconsistent 
findings among studies.           
Dysglycemia and Bone 
Osteoporosis, which is a skeletal condition characterized by lower skeletal 
mineralization in response to accelerated bone loss or making excessively minimal bone 
in the body, is a risk factor for fracture. The 2005-2010 National Health and Nutrition 
Examination Survey reported that 10.2 million American adults aged ≥ 50 years suffered 
from osteoporosis and the number is projected to increase to 17.2 million in 2030 [44]. 
The prevalence of osteoporosis among pre-diabetic and T2D men aged ≥ 50 years is 
15.1% and 33.3%, respectively [45,46]. Numerous studies have reported that pre-diabetes 
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and T2D are associated with an increased risk of osteoporotic fractures up to threefold 
[47-49], despite a normal to high bone mineral density (BMD) in patients with abnormal 
glucose metabolism. This suggests that other factors, such as hyperglycemia, 
accumulation of advanced glycosylation end products (AGEs), insulin resistance, and 
bone quality, play a crucial role in inducing the osteoporotic fractures. 
Hyperglycemia increases the expression levels of sclerostin that is inversely 
associated with areal BMD (aBMD) [50] and suppresses bone anabolic pathways through 
inhibition RNKL induced osteoclastogenesis and reduction of RNKL gene expression 
during bone remodeling [51]. Hyperglycemia also leads to diminished osteoblast activity 
and inhibited osteoblast differentiation via reduction of beta-catenin, cyclin D1, and c-
myc gene expressions [52]. AGEs decrease bone strength and impair bone cells [53]. 
Insulin resistance is negatively associated with biomarkers of bone turnover [54] and 
bone strength [55,56]. Several studies have revealed decreased bone turnover in T2D 
[57,58]. Low biomarkers of bone resorption and bone formation were observed in T2D 
patients [59].  
Few studies have assessed the association between bone mineral content (BMC) 
or aBMD and pre-diabetes. Most studies have reported no differences in aBMD at 
multiple skeletal sites between pre-diabetic and normoglycemic men [60-64]. 
Conversely, other studies revealed pre-diabetic patients had higher aBMD at the femoral 
neck (FN), hip and spine than control patients (Table 1.3) [65,66]. The effect of T2D on 
bone health have been widely studied. Previous studies evaluating bone health and T2D 
observed inconsistent findings regarding aBMD differences among patients with T2D 
and normoglycemia. Comparable, higher or lower FN, hip and spine aBMD were found 
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in T2D individuals as compared to their normoglycemic counterparts as presented in 
Table 3 [60-65,67-75]. To date, only two longitudinal studies have evaluated the 
association of baseline glycemic status with changes in aBMD at different skeletal sites. 
These studies found no differences in bone measures among men across various glycemic 
groups [62,76] (Table 1.3). However, Hamilton et al. [76] reported spine aBMD 
increased in T2D men from baseline.  
There are several possible explanations for mixed findings regarding the 
association of glycemic status with bone health. Selection of study participants was from 
varied settings including community-dwelling populations, and clinics or hospitals where 
patients managed their condition based on the treatment management from specialists or 
physicians.  Previous studies were limited by age, various methods of measuring bone 
mass, diverse study designs, and a lack of adjustment for TB FM and TB LM that may 
affect bone mass differently. Surprisingly, only two studies adjusted for TB FM and LM 
to produce an estimate of the glycemic effect on aBMD, independent of body 
composition [62,73]. Bone size and width are independent risk factors for hip fracture 
[77-79]. Recently, two studies examined the association of glycemic status with bone 
area at the FN, hip, and spine [65,74]. Despite conflicting results, pre-diabetes and T2D 
were negatively associated with FN bone area [65]. There is still gap on the association 
between glycemic status and bone area. The effect of glycemic status on changes in bone 
mass is not clear in men. Data on the transition from normoglycemia to pre-diabetes and 
T2D and reversion from pre-diabetes to normoglycemia are lacking. This dissertation 
aims to determine the association of changes in glycemic status with changes in aBMD, 
BMC, and bone area at multiple skeletal sites.  
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Table 1.3. Baseline and changes in bone mass by glycemic status. 
Study name 
Participants 
(Follow-up 
time) 
Diagnosis of 
dysglycemia Covariates 
Bone 
measures Findings 
Case-control studies 
Clinic 
Study[67] 
Italian adults 
aged 60-75 years, 
50 NG and 110 
T2D 
HbA1c and use 
of antidiabetic 
agents  
Matched by 
age, sex and 
BMI 
FN BMC  
Spine BMC 
Lower in T2D group than in NG group 
Lower in T2D group than in NG group 
Cardiovascular 
Diseases and 
Risk factors in 
Diabetes[68] 
274 Finnish men 
aged 57-68 years, 
240 NG and 34 
T2D 
HbA1c Age, BMI, 
duration of 
diabetes, 
duration of 
insulin therapy, 
insulin dose, 
calcium intake, 
and use of loop 
diuretics 
FN aBMD  
 
No difference between groups   
DCROH  [69] 105 Japanese 
men aged 74-
75years, 41 NG 
and 64 T2D 
FBG, HbA1c, 
and use of 
antidiabetic 
agents 
Matched by 
age, and BMI  
FN aBMD  
Spine aBMD 
No difference between groups  
No difference between groups   
Fremantle 
Diabetes Study 
[70] 
216 Australian 
men aged 57-76 
years, 108 NG 
and 108 T2D 
HbA1c, use of 
antidiabetic 
agents, and 
diagnosed 
between 40 and 
60 years of age 
Age and BMI FN aBMD  
hip aBMD  
Spine aBMD 
 
No difference between groups   
No difference between groups  
No difference between groups   
VHA [71] 1,100 US men 
aged 67-68 years, 
550 NG and 550 
T2D 
FBG and HbA1c Matched by 
age, BMI, 
smoking, and 
alcohol intake 
FN aBMD  
Spine aBMD 
 
Lower in T2D group than in NG group 
Greater in T2D group than in NG group 
Cross-sectional studies 
Hertfordshire 
Cohort Study 
[61] 
 432 British men 
aged 62-67 years, 
349 NG and 83 
pre-diabetes 
OGTT Age, BMI, 
cigarette, 
alcohol intake, 
current social 
class, physical 
activity 
FN aBMD  
Spine aBMD 
No difference between groups   
No difference between groups   
 
Health ABC 
Study [62] 
740 US White 
and Black men 
aged 71-77 years, 
564 NG and 176 
pre-diabetic  
OGTT NA FN aBMD  
hip aBMD  
 
No difference between groups  
No difference between groups   
Rotterdam 
Study[63] 
5,183 Dutch 
adults aged 59-
83 years,3,888 
NG and 1,295 
pre-diabetic 
OGTT Age, gender, 
BMI, smoking, 
lower limb 
disability, use 
of thiazides, 
and use of loop 
diuretics 
FN aBMD 
Spine aBMD 
No difference between groups   
No difference between groups   
BLSA [64] 394 US men 
aged 53-82 years, 
285 NG and 109 
pre-diabetic 
OGTT Age, BMI, race, 
smoking, 
multivitamin 
use, calcium 
and vitamin D 
supplementatio
n, serum 
creatinine, 
serum vitamin 
D, serum 
calcium, and 
current and 
prior 
bisphosphonate 
use 
FN aBMD 
hip aBMD  
Spine aBMD 
 
No difference between groups   
No difference between groups   
No difference between groups   
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Table 1.3. Baseline and changes in bone mass by glycemic status- continued. 
Study name 
Participants 
(Follow-up 
time) 
Diagnosis of 
dysglycemia Covariates 
Bone 
measures Findings 
ULSAM [65] 384 Swedish 
men aged 81-83 
years. 234 NG 
and 150 pre-
diabetic 
FBG Age, education, 
height, BMI, 
smoking status, 
and physical 
activity 
hip aBMD  
 
hip BA 
 
Greater in pre-diabetic group than in 
NG group 
Lower in pre-diabetic group than in NG 
group 
 
BEH [66] 1,804 Iranian 
adults aged 63-
76 years, 1,184 
NG and 620 pre-
diabetic  
FBG and HbA1c Age, gender, 
physical 
activity, current 
smoking, and 
BMI 
FN aBMD  
 
Spine aBMD  
 
Greater in pre-diabetic group than in 
NG group 
Greater in pre-diabetic group than in 
NG group 
 
 
Rancho 
Bernardo [60] 
180 US men 
aged 64-82 years, 
139 NG and 41 
T2D 
FBG, OGTT, 
and T2D 
diagnosed by 
physician  
Age, BMI, 
cigarette 
smoking, 
alcohol use, 
regular 
exercise, and  
use of diuretic 
FN aBMD  
Spine aBMD 
No difference between groups   
No difference between groups   
SAFOS [72] 217 Mexican-
American men 
aged 62- years, 
162 NG and 55 
T2D  
OGTT, self-
reported, and use 
of antidiabetic 
agents 
Age, Age2, 
BMI, smoking, 
physical 
activity, 
calcium intake, 
alcohol intake, 
and use of 
diuretics 
Spine aBMD No difference between groups   
Hertfordshire 
Cohort Study 
[61] 
402 British men 
aged 62-67 years, 
349 NG and 33 
T2D  
OGTT Age, BMI, 
cigarette, 
alcohol intake, 
current social 
class, physical 
activity 
FN aBMD  
Spine aBMD 
No difference between groups   
Greater in T2D group than in NG group 
Health ABC 
Study [73] 
1,456 US White 
and Black men 
aged 71-77 years, 
1,133 NG and 
323 T2D 
FBG, self-
reported, and use 
of antidiabetic 
agents 
Study site, 
current 
smoking, 
current 
drinking, 
performance 
battery score, 
previous 
diagnosis of 
osteoporosis, 
use of 
osteoporosis 
medications, 
TB fat, and TB 
lean  
hip aBMD  
 
Greater in T2D group than in NG group 
Health ABC 
Study [62] 
822 US White 
and Black men 
aged 71-77 years, 
564 NG and 258 
T2D 
FBG, OGTT, 
self-reported, 
and use of 
antidiabetic 
agents 
NA FN aBMD  
hip aBMD  
 
Greater in T2D group than in NG group 
Greater in T2D group than in NG group 
Rotterdam 
Study [63] 
4,451 Dutch 
adults aged 59-
83 years,3,888 
NG and 563 T2D  
OGTT and use 
of antidiabetic 
agents  
Age, gender, 
BMI, smoking, 
lower limb 
disability, use 
of thiazides, 
and use of loop 
diuretics 
FN aBMD  
Spine aBMD 
Greater in T2D group than in NG group 
Greater in T2D group than in NG group 
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Table 1.3. Baseline and changes in bone mass by glycemic status- continued. 
  
Study name 
Participants 
(Follow-up 
time) 
Diagnosis of 
dysglycemia Covariates 
Bone 
measures Findings 
BACH/Bone 
Survey[74] 
US men aged 46-
58 years, 995 NG 
and 142 TD 
Self-reported  
and use of 
antidiabetic 
agents 
Age, race, BMI, 
and physical 
activity 
FN aBMD 
Spine aBMD 
 
FN BMC 
Spine BMC 
 
FN BA 
Spine BA 
 
 
 
No difference between groups   
No difference between groups  
  
No difference between groups   
No difference between groups 
   
No difference between groups   
No difference between groups   
 
 
BLSA [64] 370 US men 
aged 53-82 years, 
285 NG and 85 
T2D 
OGTT Age, BMI, race, 
smoking, 
multivitamin 
use, calcium 
and vitamin D 
supplementatio
n, serum 
creatinine, 
serum vitamin 
D, serum 
calcium, and 
current and 
prior 
bisphosphonate 
use 
FN aBMD  
hip aBMD  
Spine aBMD 
 
No difference between groups   
No difference between groups   
No difference between groups   
ULSAM [65] 302 Swedish 
men aged 81-83 
years. 234 NG 
and 68 T2D 
FBG, self-
reported, and use 
of antidiabetic 
agents 
Age, education, 
height, BMI, 
smoking status, 
and physical 
activity  
hip aBMD  
hip BA 
 
Greater in T2D group than in NG group 
Lower in T2D group than in NG group 
 
Framingham 
Offspring 
Cohort Study 
[75] 
1,069 US adults 
aged 56-73 years, 
940 NG and 129 
T2D 
FBG and use of 
antidiabetic 
agents  
Age, gender, 
height, and 
weight  
FN aBMD No difference between groups   
 
Longitudinal studies 
Health ABC 
Study [62] 
740 US White 
and Black men 
aged 71-77 years, 
564 NG and 176 
pre-diabetic 
(Over 4-year 
follow-up) 
OGTT *See footnote FN aBMD  
hip aBMD  
 
No difference between groups  
No difference between groups   
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Table 1.3. Baseline and changes in bone mass by glycemic status- continued. 
Abbreviation: T2D, type 2 diabetic; HbA1c, hemoglobin A1c, BMI, body mass index; FN, femoral neck; BMC, bone mineral content; 
NG, normoglycemic; aBMD, areal bone mineral density; DCROH, Diabetes Clinic of Rakuwakai Otowa Hospital; FBG, fasting blood 
glucose; VHA, Veterans Health Administration; OGTT, oral glucose tolerance test; BEH, Bushehr Elderly Health program; SAFOS, 
Sant Antonio Family Osteoporosis Study; Health ABC Study, Health, Aging and Body Composition Study; NA, no adjustment for 
covariates; BACH/Bone Survey, Baston Area Community Health/Bone Survey; BA, bone area; BLSA, Baltimore Longitudinal Study 
of Aging; ULSAM, Uppsala Longitudinal Study of Adult Men.     
*FN models adjusted for age, baseline weight, weight change during follow-up, TB lean mass, IL-6, use of oral steroid, and baseline 
hip aBMD. 
*Hip models adjusted for age, baseline weight, weight change during follow-up, TB lean mass, IL-6, use of vitamin D supplement, 
and baseline FN aBMD. 
 
 
 
Dysglycemia and Lipid Profile 
Insulin resistance, central to the pathogenesis of pre-diabetes and T2D, 
contributes to disturbances in lipid and lipoprotein metabolism. Dyslipidemia, 
characterized by hypertriglyceridemia, an increased concentration of small, dense low-
density lipoprotein cholesterol (LDL-C) and a decreased concentration of high-density 
lipoprotein cholesterol (HDL-C) is common in pre-diabetic and T2D patients, resulting in 
an increased risk of cardiovascular disease (CVD) [3,80]. Elevated fatty acids released 
from the adipocyte into the circulation is induced by insulin resistance in pre-diabetes and 
T2D. The flux of free fatty acids to the liver enhances synthesis and secretion of very 
low-density lipoprotein (VLDL) leading to an increased concentration of triglyceride 
(TG). The exchange between TG of VLDL and cholesterol esters of LDL and HDL is 
regulated by cholesterol ester transfer protein. Hepatic lipase hydrolyzes TG in LDL and 
Study name 
Participants 
(Follow-up 
time) 
Diagnosis of 
dysglycemia Covariates 
Bone 
measures Findings 
Longitudinal studies - continued 
Health ABC 
Study [62] 
822 US White 
and Black men 
aged 71-77 years, 
564 NG and 258 
T2D 
(Over 4-year 
follow-up) 
FBG, OGTT, 
use of 
antidiabetic 
drug, and self-
reported 
*See footnote FN aBMD  
hip aBMD  
 
No difference between groups  
No difference between groups   
Fremantle 
Diabetes Study 
[76] 
16 Australian 
T2D men aged 
56-74 years (over 
5-year follow-up)  
HbA1c, use of 
antidiabetic 
agents, and 
diagnosed 
between 40 and 
60 years of age 
Age and BMI FN aBMD 
hip aBMD  
Spine aBMD 
 
No change from baseline  
No change from baseline 
Increased from baseline  
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HDL particles resulting in smaller, denser LDL particles and a lower concentration of 
HDL-C through enhanced HDL clearance from plasma [81-83].  
According to the National Health and Nutrition Examination Survey, the 
prevalence of dyslipidemia among pre-diabetic and T2D adults aged ≥ 20 years in the US 
in 2011-2014 was 51.2% and 63.2%, respectively [84]. Since dyslipidemia in patients 
with pre-diabetes is identical to those with T2D, lipid target goals for pre-diabetes should 
be similar to T2D [3]. The primary target goal for LDL-C is <100 mg/dL in individuals 
with pre-diabetes and T2D without coronary heart disease (CHD) and <70 mg/dL in 
individuals with pre-diabetes or T2D and CHD. If TG is >200 mg/dL, the secondary 
target goal for non-HDL-C is <130 mg/dL in pre-diabetic and T2D individuals. The third 
target goal for HDL-C is >40 mg/dL in pre-diabetic and T2D individuals [85,86]. The 
ADA criteria for lipid targets are <100 mg/dL for LDL-C, >40 mg/dL for HDL-C in men 
and <150 mg/dL for TG [87].  
The association of pre-diabetes with lipid and lipoprotein abnormalities has been 
extensively investigated, but the diagnosis of pre-diabetes (impaired fasting glucose 
(IFG) versus impaired glucose tolerance (IGT)) contributes to inconsistent findings. IFG 
has consistently shown a positive association with TC, LDL-C, and TG, but no 
association with HDL-C (Table 4) [88-90]. On the other hand, IGT has an opposite 
association with lipid profile, including negative correlation with HDL-C, positive 
correlation with TG, and no correlations with TC and LDL-C (Table 4) [88-92].  
The site of insulin resistance in the pre-diabetic state can explain discrepancies 
among cross-sectional studies. In the presence of IFG, VLDL is elevated in response to 
19 
 
increased hepatic TG lipoprotein synthesis. This leads to increased production and 
secretion of hepatic apo B-100 resulting in hypertriglyceridemia [93]. Hyperinsulinemia 
promotes free fatty acid flux to the liver through suppression of adipocyte lipolysis with 
increases in the hepatic secretion of VLDL resulting in hypertriglyceridemia. Also, a 
decrease in lipoprotein lipase activity of adipose tissue contributes to reduced VLDL 
breakdown and elevations in TG concentrations [93]. In the state of IGT, impaired fatty 
acid uptake and oxidation in skeletal muscle lead to the accumulations of free fatty acids 
and lipids that promote hepatic synthesis and secretion of TG-enriched VLDL particles 
that are exchanged for TG-enriched LDL and HDL particles by cholesterol ester transfer 
protein [94,95]. Hepatic TG lipase hydrolyzes TG-enriched LDL and HDL particles and 
accelerates clearance of LDL and HDL particles resulting in an increase in small, dense 
LDL particles and a decrease in concentration of HDL-C [95].  
It has previously been observed that TC and LDL-C normally remain unaltered in 
individuals with T2D compared to their normoglycemic counterparts [91,92,96,97]. 
However, atherogenic dyslipidemia, comprising of decreased HDL-C concentration and 
increased TG concentration, is common in T2D patients as presented in Table 3 [88,90-
92,96,97]. Up to now, little attention has been paid to the effects of changes in glycemic 
status on changes in lipids and lipoproteins. The San Antonio Heart Study examined the 
relation between conversion from normoglycemia or pre-diabetes to T2D and baseline 
lipid profile over 8-year follow-up. These investigators found no difference in the lipid 
profiles between converters to T2D and non-converters as shown in Table3 [98,99].  
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Only two clinical trials have attempted to investigate changes in glycemic status 
in relation to changes in lipid profile [100,101]. The experimental data are rather 
controversial, and there is no general agreement about reversion from pre-diabetes to 
normoglycemia associated with improvement in lipid profile and conversion from 
normoglycemia/pre-diabetes to T2D being associated with worsening lipid profile. 
Regression from pre-diabetes to normoglycemia was correlated with an increase in HDL-
C and a reduction in TG, whereas progression from normoglycemia to pre-diabetes was 
associated with an increase in LDL-C and a decrease in HDL-C. Conversion from pre-
diabetes to T2D was associated with declines in LDL-C and HDL-C [100]. Nevertheless, 
Nanditha et al. [101] reported no differences in changes in TC, HDL-C, and TG among 
pre-diabetic men who reverted to normoglycemia and those who remained pre-diabetic, 
while increases in TC and TG were observed in pre-diabetic men who progressed to T2D 
compared to those who remained pre-diabetic throughout the study (Table 4) [101]. 
Much uncertainty still exists about the relation between regression to normoglycemia or 
progression to pre-diabetes and T2D and changes in lipids and lipoproteins. This 
dissertation seeks to determine whether the transition from pre-diabetes to 
normoglycemia is associated with favorable lipid profile and transition from 
normoglycemia or pre-diabetes to T2D is associated with worsening lipid profile. 
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Table 1.4. Baseline and changes in lipid profile by glycemic status.  
Study name 
Participants 
(Follow-up 
time) 
Diagnosis of 
dysglycemia Covariates 
Lipid 
measures Findings 
Case-control studies 
Screening 
Program for 
Risk of T2D 
[88] 
 
725 Bulgarian 
adults aged 41-
64 years, 477 NG 
and 248 IFG 
FBG Matched by age 
and BMI 
TC 
LDL-C 
HDL-C 
TG 
Greater in IFG group than in NG group  
Greater in IFG group than in NG group  
Lower in IFG group than in NG group 
Greater in IFG group than in NG group  
Screening 
Program for 
Risk of T2D 
[88] 
674 Bulgarian 
adults aged 41-
69 years, 477 NG 
and 197 IGT 
OGTT Matched by age 
and BMI 
TC 
LDL-C 
HDL-C 
TG 
No difference between groups  
No difference between groups  
Lower in IGT group than in NG group 
Greater in IGT group than in NG group 
Screening 
Program for 
Risk of T2D 
[88] 
795 Bulgarian 
adults aged 44-
69 years, 477 NG 
and 318 T2D 
 FBG and 
OGTT 
Matched by age 
and BMI 
TC 
LDL-C 
HDL-C 
TG 
Greater in T2D group than in NG group  
No difference between groups  
Lower in T2D group than in NG group 
Greater in T2D group than in NG group  
Cross-sectional studies 
Rancho 
Bernardo 
Study [91] 
833 US men 
aged 69-74 years, 
593 NG and 240 
IGT  
OGTT Age, BMI, 
smoking, 
alcohol intake, 
and excerise  
TC 
LDL-C 
HDL-C 
TG 
No difference between groups  
No difference between groups  
Lower in IGT group than in NG group 
No difference between groups  
Rancho 
Bernardo 
Study [91] 
 754 US men 
aged 69-75 years, 
593 NG and 161 
T2D 
FBG, OGTT, 
and T2D 
diagnosed by 
a physician   
Age, BMI, 
smoking, 
alcohol intake, 
and excerise 
TC 
LDL-C 
HDL-C 
TG 
No difference between groups  
No difference between groups  
Lower in T2D group than in NG group 
Greater in T2D group than in NG group 
Study Clinic 
[96] 
189 US White 
and Hispanic 
men aged 32-57 
years, 148 NG 
and 41 T2D  
OGTT Age and BMI LDL-C 
HDL-C 
TG 
 
No difference between groups  
Lower in T2D group than in NG group 
Greater in T2D group than in NG group 
UKPDS [97] 2191 British men 
aged 43-61 years, 
52 NG and 2139 
T2D  
FBG NA TC 
LDL-C 
HDL-C 
TG 
No difference between groups  
No difference between groups  
Lower in T2D group than in NG group 
Greater in T2D group than in NG group 
DECODE [89] 7141 European 
men aged 35-74 
years, 5403 NG 
and 1738 IFG 
FBG Age, study 
center, waist 
circumference, 
smoking, 
systolic blood 
pressure, and 
fasting insulin  
TC 
HDL-C 
TG 
TC/HDL 
Greater in IFG group than in NG group  
No difference between groups  
Greater in IFG group than in NG group 
Greater in IFG group than in NG group 
DECODE [89]  6505 European 
men aged 35-74 
years, 5403 NG 
and 1102 IGT 
OGTT Age, study 
center, waist 
circumference, 
smoking, 
systolic blood 
pressure, and 
fasting insulin 
TC 
HDL-C 
TG 
TC/HDL 
No difference between groups  
Lower in IGT group than in NG group  
Greater in IGT group than in NG group 
Greater in IGT group than in NG group 
Community-
dwelling 
adults: Rome-
Tor and 
Catanzaro 
Areas [102] 
544 Italian adults 
aged 28-64 years, 
416 NG and 128 
pre-diabetes 
HbA1c Age and gender TC 
HDL-C 
TG 
No difference between groups  
Lower in pre-diabetic group than in NG 
group 
Greater in pre-diabetic group than in NG 
group 
 
METSIM [90] 7379 Finish men 
aged 50-64 years, 
3034 NG and 
4345 IFG 
FBG Age, family 
history of 
diabetes, 
physical activity 
during leisure 
time, BMI, 
waist 
circumference, 
and use of 
statins 
TC 
LDL-C 
HDL-C 
TG 
Greater in IFG group than in NG group 
Greater in IFG group than in NG group 
No difference between groups  
Greater in IFG group than in NG group 
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Table 1.4. Baseline and changes in lipid profile by glycemic status- continued.  
Study name 
Participants 
(Follow-up 
time) 
Diagnosis of 
dysglycemia Covariates 
Lipid 
measures Findings 
METSIM [90] 3346 Finish men 
aged 50-67 years, 
3034 NG and 
312 IGT 
OGTT Age, family 
history of 
diabetes, 
physical activity 
during leisure 
time, BMI, 
waist 
circumference, 
and use of 
statins 
TC 
LDL-C 
HDL-C 
TG 
No difference between groups  
No difference between groups  
Lower in IGT group than in NG group 
Greater in IGT group than in NG group 
 
METSIM [90]  Finish men aged 
50-66 years, 
3034 NG and 
650 T2D 
FBG and 
OGTT 
Age, family 
history of 
diabetes, 
physical activity 
during leisure 
time, BMI, 
waist 
circumference, 
and use of 
statins 
TC 
LDL-C 
HDL-C 
TG 
Greater in T2D group than in NG group 
No difference between groups  
Lower in T2D group than in NG group 
Greater in T2D group than in NG group 
 
PREDAPS 
[103] 
1452 Spanish 
adults aged 30-
74 years, 838 NG 
and 614 pre-
diabetes 
FBG and 
HbA1c 
Age, gender, 
educational 
level, and 
family history 
of diabetes 
 
TC 
LDL-C 
HDL-C 
TG 
No difference between groups  
No difference between groups  
Lower in pre-diabetic group than in NG 
group 
Greater in pre-diabetic group than in NG 
group 
 
CATAMERI 
[104] 
 894 Italian 
adults aged 40-
53 years, 602 NG 
and 292 pre-
diabetes 
HbA1c Age, gender, 
and BMI 
 
TC 
HDL-C 
TG 
No difference between groups  
Lower in pre-diabetic group than in NG 
group 
Greater in pre-diabetic group than in NG 
group 
 
CATAMERIS 
[92] 
953 Italian adults 
aged 30-64 years, 
721 NG and 232 
IGT 
OGTT Age, gender, 
and waist 
circumference 
TC 
LDL-C 
HDL-C 
TG 
TG/HDL 
No difference between groups  
No difference between groups  
Lower in IGT group than in NG group 
Greater in IGT group than in NG group 
Greater in IGT group than in NG group  
 
CATAMERIS
[92] 
779 Italian adults 
aged 30-64 years, 
721 NG and 58 
T2D 
OGTT Age, gender, 
and waist 
circumference 
TC 
LDL-C 
HDL-C 
TG 
TG/HDL  
No difference between groups  
No difference between groups  
Lower in T2D group than in NG group 
Greater in T2D group than in NG group 
Greater in T2D group than in NG group 
      
CATAMERI 
[105] 
644 Italian adults 
aged 27-66 years, 
425 NG and 239 
pre-diabetes 
HbA1c Age, gender, 
and BMI 
 
TC 
LDL-C 
HDL-C 
TG  
No difference between groups  
No difference between groups  
Lower in pre-diabetic group than in NG 
group 
Greater in pre-diabetic group than in NG 
group 
 
Longitudinal studies 
Sant Antonio 
Heart Study 
[98] 
614 Mexican 
American adults 
aged 25-64 years, 
571 NG to NG 
and 43 NG/IGT 
to T2D (8-year 
follow-up) 
FBG, OGTT, 
and use of 
anti-diabetic 
agents 
Age, BMI, and 
fasting insulin 
concentration 
TC 
LDL-C 
HDL-C 
TG 
No difference between groups  
No difference between groups  
No difference between groups  
No difference between groups  
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Table 1.4. Baseline and changes in lipid profile by glycemic status- continued.  
 
Abbreviation: T2D, type 2 diabetes; NG, normoglycemic, IFG, impaired fasting glucose; FBG, fasting blood glucose; BMI, body 
mass index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, 
triglyceride; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; UKPDS, United Kingdom Prospective Diabetes 
Study; NA, no adjustment for covariates; DECODE, Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe; 
TC/HDL TC to HDL-C ratio, HbA1c, hemoglobin A1c; METSIM, Metabolic Syndrome In Men; PREDAPS, Primary Health Care on 
the Evolution of Patients with Prediabetes; CATAMERI, CATAnzaro Metabolic Risk factor;  CATAMERIS, CATAnzaro Metabolic 
Risk factor Study; TG/HDL, TG to HDL-C ratio; NG to NG, normoglycemic remained normoglycemic; NG/IGT to T2D, 
normoglycemic or pre-diabetic converted to type 2 diabetes; IG to NG, pre-diabetic reverted to normoglycemia; IGT to IGT, pre-
diabetic remained pre-diabetic; and IGT to T2D, pre-diabetic converted to type 2 diabetes. 
 
Statement of the Problem  
There have been increases in the number of cases of pre-diabetes and T2D among 
US adults due to the aging population and the increase in the prevalence of pre-diabetes 
and T2D among US adults may be due to an increase in the rate of obesity. The growing 
economic burden of pre-diabetes and T2D is attributed to the increasing prevalence as 
Study name 
Participants 
(Follow-up 
time) 
Diagnosis of 
dysglycemia Covariates 
Lipid 
measures Findings 
San Antonio 
Heart Study  
[99] 
1734 Mexican 
and Non-
Hispanic White 
American adults 
aged 25-64 years, 
1539 NG to NG 
and 195 NG/IGT 
to T2D (7-year 
follow-up) 
OGTT and 
use of anti-
diabetic 
agents 
Age, gender, 
ethnicity, 
fasting glucose, 
waist 
circumference, 
and insulin 
resistance 
LDL-C 
HDL-C 
TG 
No difference between groups  
No difference between groups  
No difference between groups  
 
Lifestyle 
Intervention 
Program [101] 
343 Asian Indian 
men aged 41-52 
years, 192 IG to 
NG and 151 IGT 
to IGT (2-year 
follow-up) 
OGTT Age, treatment 
group, family 
history of 
diabetes, 
baseline 2-hour 
plasma glucose, 
baseline and 
change in BMI, 
HOMA-IR, 
insulinogenic 
index, dietary 
energy intake, 
and physical 
activity   
TC 
HDL-C 
TG 
No difference between groups  
No difference between groups  
No difference between groups  
 
Lifestyle 
Intervention 
Program [101] 
343 Asian Indian 
men aged 41-52 
years, 151 IGT to 
IGT and 79 IGT 
to T2D (2-year 
follow-up) 
OGTT Age, treatment 
group, family 
history of 
diabetes, 
baseline 2-hour 
plasma glucose, 
baseline and 
change in BMI, 
HOMA-IR, 
insulinogenic 
index, dietary 
energy intake, 
and physical 
activity   
TC 
 
HDL-C 
TG 
Increased in IGT to T2D group compared 
to IGT to IGT group 
No difference between groups  
Increased in IGT to T2D group compared 
to IGT to IGT group 
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well as the use and cost of health care services [106,107]. The primary key to prevention 
of prediabetes and T2D is lifestyle modifications. There is accumulating epidemiological 
evidence indicating that unfavorable body composition [108-112] and lipid profile [113-
117] are risk factors for pre-diabetes and T2D, but little is known about the effect of 
change in glycemic status on subsequent changes in lipid profile. Until now, only two 
clinical trials have shown that reversion from pre-diabetes to normoglycemia had 
favorable changes in lipid biomarkers [100,101]. To date, no observational longitudinal 
study has determined the association of change in glycemic status (progression from 
normoglycemia or pre-diabetes to T2D or regression from pre-diabetes to 
normoglycemia) with changes in body composition and lipid profiles. Only three 
longitudinal studies have evaluated the impact of pre-diabetes and T2D on changes in 
BMC and aBMD at different bone sites, but the findings are unclear [62,67,118]. To fill 
these critical gaps and move the research field, the present study was to investigate the 
association of change in glycemic status with changes in body composition, measures of 
bone health (bone area, BMC, and aBMD at multiple sites), and lipid profiles in male 
adults across a wide age range (20 to 66 years).  
Overall Aim 
The overall objective of this dissertation was to investigate the effects of baseline 
and changes in glycemic status on baseline and changes in body composition, bone, and 
lipid profile. This dissertation used data from the ongoing longitudinal South Dakota 
Rural Bone Health Study (SDRBHS) of a cohort of 1,271 participants aged 20 to 66 years 
who were enrolled between 2001 and 2004. The analysis was limited to men due to the 
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higher prevalence of pre-diabetes and T2D in men than women, and data from the 
baseline and year three follow-up visits were used.   
Specific Aims 
Three specific aims were addressed:  
Aim 1. To examine the associations between baseline and changes in glycemic status with 
baseline and changes over three years in TB, trunk, and appendicular FM and LM.  
The following hypotheses were tested:  
1. Men with prediabetes or T2D at baseline would have higher TB and trunk fat 
measurements but lower appendicular fat than normoglycemic men. 
2. Men who were normoglycemic at baseline and developed either prediabetes or 
T2D would have increases in TB and trunk FM, and decreases in TB and 
appendicular LM over the three-year study compared with men who remained 
normoglycemic. 
3. Among men with prediabetes at baseline, the changes in TB and trunk FM and 
LM would differ over the three-year study depending on whether they remained 
prediabetic or developed T2D versus reverting to a normoglycemic state. Those 
who develop T2D would gain TB FM and lose LM, while those reverting to 
normoglycemia would lose FM and maintain or gain LM.  
4. Men with T2D at baseline would have decreases in TB and trunk LM over the 
three-year study compared to normoglycemic men. 
Aim 2. To determine both cross-sectional and longitudinal relationships between bone 
measures (BMC and aBMD) and glycemic status in men after taking into account 
differences in body composition. 
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The following hypotheses were tested:  
1. Men with pre-diabetes or T2D at baseline would have higher BMC and aBMD 
compared to normoglycemic individuals, but these differences would not remain 
significant when controlling for differences in body composition. 
2. Normoglycemic or pre-diabetic men who developed T2D would have similar 
changes in BMC and aBMD as men who remained normoglycemic after adjusting 
for differences in body composition. 
3. Among men with pre-diabetes, the change in BMC and aBMD would differ 
depending on whether they developed T2D or reverted to the normoglycemic 
state.  Men developing T2D would have decreases in BMC and aBMD compared 
to men who remain pre-diabetic after adjusting for body composition, while those 
reverting to a normoglycemic state would maintain or increase their BMC and 
aBMD. 
Aim 3. To determine the effects of cross-sectional and longitudinal changes in glycemic 
status on baseline and changes in lipid biomarkers and ratios. 
The following hypotheses were tested:   
1. Pre-diabetic and T2D men would have greater TC, LDL-C, TG, cardiac risk ratio 
(CRR), and atherogenic index of plasma (AIP) and lower HDL concentrations 
than normoglycemic men at baseline. 
2. TC, LDL-C, TG, RCC, and AIP concentrations would increase, and HDL 
concentrations would decrease, in normoglycemic men who developed pre-
diabetes or T2D.  
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3. TC, LDL-C, TG, CRR, and AIP concentrations would decrease, and HDL 
concentrations would increase, in pre-diabetic men who reverted to 
normoglycemia compared to prediabetic men who remained pre-diabetic. 
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Abstract 
Objective: This study sought to evaluate the associations between changes in glycemic 
status and changes in total body (TB), trunk, and appendicular fat (FM), and lean mass 
(LM) in men.  
Methods: A population-based study of men aged 20–66 years at baseline were included 
in cross-sectional (n = 430) and three-year longitudinal (n = 411) analyses. Prediabetes 
was defined as fasting glucose 100–125 mg/dL. Type 2 diabetes (T2D) was determined 
by: self-reported diabetes, current anti-diabetic drug use (insulin/oral hypoglycemic 
agents), fasting glucose (≥126 mg/dL), or non-fasting glucose (≥200 mg/dL). Body 
composition was evaluated by dual-energy X-ray absorptiometry.  
Results: Longitudinal analyses showed that changes in TB FM and LM, and appendicular 
LM differed among glycemic groups. Normoglycemic men who converted to prediabetes 
lost more TB and appendicular LM than men who remained normoglycemic (all, p < 
0.05). Normoglycemic or prediabetic men who developed T2D had a greater loss of TB 
and appendicular LM than men who remained normoglycemic (both, p < 0.05). T2D men 
had greater gains in TB FM and greater losses in TB and appendicular LM than men who 
remained normoglycemic (all, p < 0.05).  
Conclusion: Dysglycemia is associated with adverse changes in TB and appendicular 
LM. 
Keywords: prediabetes; type 2 diabetes; total body fat; total body lean; appendicular fat; 
appendicular lean; body composition; cohort study 
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Introduction 
Prediabetes and type 2 diabetes (T2D) are major public health issues in the United 
States. The national prevalence of prediabetes and T2D among adults aged ≥20 years has 
increased over time, with the prevalence of prediabetes rising from 26% in 1988–1994 [1] 
to 37% in 2009–2012 [2]. Recent estimates from the Centers for Disease Control and 
Prevention indicate that 15–30% of prediabetic cases progress from impaired fasting 
glucose or impaired glucose tolerance to T2D within five years. There are currently 25.8 
million adults in the United States with prediabetes that will develop T2D by 2020, which 
will double the number of individuals affected by T2D [3]. The prevalence of T2D rose 
from 7% in 2005 to 12% in 2011 [4], and is projected to increase 165% by 2050 [5]. 
Case-control and cross-sectional studies have reported inconsistent associations of 
total body (TB), trunk, and appendicular fat mass (FM) and lean mass (LM) with 
prediabetes and T2D diabetes in middle-aged and older adults, including a positive 
association [6], an inverse association [7–10], and no association [6,8,9]. Prospective 
studies aimed at investigating the relationship between baseline glycemic status and 
subsequent changes in TB and regional distribution of FM and LM are sparse and 
inconclusive. Some studies reported differences in body composition measurements among 
glycemic groups [11–14], but others did not find differences [15,16]. The possible 
explanation for inconsistent findings includes different durations of follow-up period, 
sample size, and other covariates that were not adjusted for when investigating the 
association between various measures of body composition and glycemic status. We found 
no epidemiological studies that investigated the association between glycemic status (men 
with prediabetes who revert to normoglycemia, or men who are normoglycemic or 
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prediabetic at baseline and convert to T2D) and changes in the TB and regional distribution 
of FM and LM. 
The objective of the present analysis was to examine the associations between baseline 
and changes in glycemic status with baseline and changes over three years in TB, trunk, 
and appendicular FM and LM. The following a priori hypotheses were tested: (1) men with 
prediabetes or T2D at baseline would have higher TB and trunk fat measurements but lower 
appendicular fat than normoglycemic men; (2) men who were normoglycemic at baseline 
and developed either prediabetes or T2D would have increases in TB and trunk FM, and 
decreases in TB and appendicular LM over the three-year study compared with men who 
remained normoglycemic; (3) among men with prediabetes at baseline, the changes in TB 
and trunk FM and LM would differ over the three-year study depending on whether they 
remained prediabetic or developed T2D versus reverting to a normoglycemic state. Those 
who develop T2D would gain TB FM and lose LM, while those reverting to 
normoglycemia would lose FM and maintain or gain LM; and (4) men with T2D at baseline 
would have decreases in TB and trunk LM over the three-year study compared to 
normoglycemic men. 
Methods 
Study Population 
The South Dakota Rural Bone Health Study is a population-based longitudinal study 
designed to investigate the impact of lifestyle factors on bone and body composition. The 
design and rationale of the study have been described elsewhere [17]. Briefly, adults aged 
20 to 66 years, from eight counties in eastern South Dakota, were eligible for enrollment. 
50 
 
A total of 1271 participants were recruited between 2001–2004 (baseline), and followed 
for an average of 3.0 years (range of 2.8 to 3.8 years), and the current analysis was limited 
to men (n = 544). Among those participants, 410 men farmed at least 75% of their lives 
(rural) and 134 men never lived on an active farm (non-rural). The rural population was 
divided into Hutterites and non-Hutterites. A Hutterite was defined as a participant of 
Hutterite descent who resided on a Hutterite colony. Hutterites are an Anabaptist religious 
group who believe in isolated communal living and self-sufficiency through an 
agriculturally advanced lifestyle. Non-Hutterites were randomly selected from the eight-
county region as described elsewhere [17]. 
       Men with chronic use (> six months) of immunosuppressants, anticonvulsants, or 
steroids or a diagnosis of type 1 diabetes mellitus at baseline were not eligible for 
inclusion in the original cohort. For baseline analyses, we excluded men with missing 
glucose measures at either baseline (n = 12) or follow-up (n = 34), baseline body 
composition measurements (n = 23), or men who withdrew from the study (n = 45) 
(Figure 2.1). For follow-up analyses, we further excluded men who did not have body 
composition measurements at follow-up (n = 19). These exclusions led to 430 men in the 
baseline analyses and 411 in the follow-up analyses. The study was approved by the 
South Dakota State University Institutional Review Board (IRB#1406004), and informed 
consent was obtained from all of the participants. 
Assessment of Covariates 
Questionnaires were administered at study enrollment and at three years to obtain 
information on demographic and lifestyle characteristics as well as quarterly physical 
activity and dietary intake recalls. Information on smoking status and specific details 
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regarding the use of prescription drugs was not collected at baseline; however, an 18-month 
survey was used to obtain this information. Participants were asked to provide information 
on types of smoking, such as cigarettes, cigars, and pipes, and were classified as smokers 
or non-smokers. The presence or absence of hypertension at 18 months was based on self-
reported information on the use of antihypertensive medication.  
Anthropometric Measures 
Body height and weight were measured in lightweight clothes without shoes using a 
calibrated stadiometer and scale. Standing height was measured to the nearest 0.5 cm in 
duplicate with a stadiometer (Seca, Chino, CA, USA). A third measurement was taken if 
the discrepancy between the duplicate height measurements was more than 0.5 cm. Weight 
was measured to the nearest 0.1 kg with a digital scale (Seca Model 770, Chino, CA, USA). 
Physical Activity Assessment 
The Paffenbarger Physical Activity Questionnaire (PPAQ) was used to measure the 
average amount of time spent in sedentary behaviors and different intensity levels of 
physical activity during the past week [18]. Participants were asked to recall how many 
hours on their usual weekday and weekend day they spent sleeping, sitting, and engaging 
in moderate or vigorous intensity activity. Since the time spent in sleeping, sitting, and 
participating in moderate plus vigorous activity was measured, the remaining time was 
considered light activity. The PPAQ was administered quarterly over the first three years 
of the study. To properly report participants’ physical activity, trained personnel 
administered the PPAQ by interview. The average time spent in sitting and moderate-plus-
vigorous activity, as well as the average sleeping time, was calculated. The validity and 
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reliability of the PPAQ have been established to measure physical activity intensities in 
men [19] and rural populations [20]. 
Dietary Assessment 
Dietary intake was assessed using 24-h dietary recalls that were conducted at similar 
times as the activity recall. Trained interviewers administered 24-h dietary recalls, and 
dietary recall data were analyzed using Nutritionist Pro software (version 2.3.1, 2004, First 
DataBank, Inc., San Bruno, CA, USA) to estimate macronutrient and micronutrient intakes. 
For foods not available in the Nutritionist Pro software, the nutrient composition of the 
foods was obtained from recipes and entered into the diet analysis software. Activity levels 
and nutrient intakes at baseline were the averages of the baseline, three-month and six-
month recalls, and measures at the 36-month visit were the averages of the 30-month, 33-
month, and 36-month recalls. 
Ascertainment of Glycemic Status 
According to American Diabetes Association classifications, individuals with a fasting 
blood glucose of 100 mg/dL to 125 mg/dL were classified as having prediabetes [21]. T2D 
was determined by one of the following criteria: self-reported T2D, current use of an anti-
diabetic drug (insulin or oral hypoglycemic agents), or a fasting blood glucose 
concentration ≥126 mg/dL or a non-fasting blood glucose concentration ≥200 mg/dL [21]. 
The same criteria for the diagnosis of prediabetes and T2D were applied at both the baseline 
and three-year visits. Attempts were made to obtain fasting blood samples at each visit, 
and measurements were made in the field from a sample of venous whole blood (with 
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added ethylenediaminetetraacetic acid) using an Accu-Check Advantage glucometer 
(Roche Diagnostics, Indianapolis, IN, USA).  
 Body Composition Measurements 
Body composition was assessed using dual-energy x-ray absorptiometry (DXA) 
(Discovery, Software Version 12.01, Hologic, Waltham, MA, USA). A TB scan was 
completed with boundaries for the various anatomical regions set according to 
manufacturer’s specifications. The step phantom scan for body composition calibration 
was completed weekly as suggested by the manufacturer. Prior to DXA measurements, the 
Hologic spine phantom was scanned for quality control. All of the scans were analyzed by 
the same technician who was certified by the International Society of Clinical 
Densitometry. Scan results were deleted for obese participants with an equivalent epoxy 
thickness greater than 12 inches, as determined by the Hologic software, per manufacturer 
recommendations (n = 16 men: n = seven Hutterite, n = four rural, n = five non-rural). 
DXA-derived measurements of TB, trunk and appendicular FM and LM were expressed in 
kilograms. Our coefficients of variation for TB FM and LM assessed in 15 adults (one 
male) using triplicate scans with repositioning between each scan are <1.5%. 
 Statistical Analysis 
All of the continuous variables were tested for normality before performing the 
analyses. Analysis of variance adjusting for multiple comparisons for continuous variables 
and a Fisher’s exact test for categorical variables were used to determine statistical 
significance in baseline characteristics among the glycemic categories. The annual absolute 
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change in each body composition measure was calculated as the follow-up value minus 
baseline value divided by length of follow-up in years.  
Multiple regression models were used to estimate marginal means ± standard error of 
the mean (sem) for baseline body composition parameters and changes in outcome 
measures by different categories of glycemic status. Differences in marginal means among 
glycemic groups were evaluated using post hoc contrast tests based on the hypotheses. A 
priori determined covariates (age at baseline, height, population group, percent time in 
moderate-plus-vigorous activity, and total daily caloric intake) were included in all of the 
models, since they were found to be associated with at least one body composition measure. 
The multiple regression models that were used for baseline analyses included these 
covariates, and the FM model included the LM of the same compartment (TB, trunk, or 
appendicular), and the LM model included covariates plus the FM of the same 
compartment. Multiple regression models for the longitudinal analyses were adjusted for 
the same covariates, as well as changes in percent time in moderate-plus-vigorous activity 
and total daily caloric intake between baseline and three-year follow-up, baseline measure 
of the specific body compartment (TB, trunk, or appendicular), and baseline and annual 
changes in the FM or LM of same compartment. Due to issues with multicollinearity and 
the problem of body composition measures being components of both body mass index 
(BMI) and weight, neither BMI nor weight was included as covariates. The assumptions 
of linearity, normality, and homoscedasticity were evaluated visually to ensure no violation 
of assumptions. All of the analyses were performed using JMP software (version 13, SAS 
Institute, Cary, NC, USA), and the statistical significance level was set at p < 0.05 (two-
tailed).  
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Results  
 Subject Characteristics 
At the baseline visit, 358 (83.2%) of the men were normoglycemic, 51 (11.9%) were 
prediabetic based on fasting glucose concentrations, and 21 (4.9%) had T2D (14 self-
reported a medical diagnosis, six based on fasting glucose, and one based on non-fasting 
glucose). Of the 345 men who were normoglycemic at baseline and for whom glucose and 
body composition measurements were available at three years, 272 (78.9%) remained 
normoglycemic, 65 (18.8%) progressed to prediabetes, and eight (2.3%) progressed to T2D 
(five based on fasting glucose, one based on non-fasting glucose, one self-reported a 
medical diagnosis, and one taking anti-diabetic medication). Among the 48 prediabetic 
men, 19 (39.6%) remained prediabetic, 25 (52.1%) reverted to normoglycemic, and four 
(8.3%) progressed to T2D based on fasting glucose concentrations. Of the 18 T2D men 
who were diabetic throughout the study, four (22.2%) self-reported a medical diagnosis, 
11 (61.1%) were taking anti-diabetic medication, and three (16.7%) had T2D based on 
fasting glucose concentrations.  
Participant characteristics by glycemic categories at baseline and follow-up are 
summarized in tables 2.1 and 2.2. The mean age (+ sem) was 42.7 ± 0.6 years (range: 20 
to 66 years), and men with T2D at baseline were older than those who were 
normoglycemic. The study population was 37.4% Hutterite, 37.2% rural non-Hutterite, and 
25.4% non-rural. Hutterites and married men had a higher prevalence of prediabetes and 
T2D than non-Hutterites and single men. Men with prediabetes weighed more than 
normoglycemic men. A higher percentage of prediabetic and T2D men were taking 
antihypertensive medication than normoglycemic men, and carbohydrate intake was 
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greater in normoglycemic men than in prediabetic and T2D men. At follow-up, men with 
T2D had lower caloric and carbohydrate intake than men who remained normoglycemic 
throughout the study or men who were normoglycemic and developed prediabetes (Table 
2.2). Prediabetic men who remained prediabetic at three years increased their carbohydrate 
intake, and men who remained normoglycemic throughout the study increased their weight, 
time spent in moderate-plus-vigorous activity, and average daily fat intake. The overall 
mean changes over the three-year study in percent time in moderate-plus-vigorous activity 
and average dietary intake of calories, carbohydrates, fat, and protein were not significant 
(mean changes were 0.6 ± 0.4%, 10 ± 28 kcal, 1.0 ± 3.8 g, 3.0 ± 1.6 g, and 0.0 ± 1.5 g, 
respectively), and changes in caloric and macronutrient intakes did not differ by glycemic 
categories (data not shown).  
Cross-Sectional Assessment of Baseline Body Composition in Men with Prediabetes or 
Type 2 Diabetes  
There were no differences in TB, trunk, or appendicular FM or LM among the three 
glycemic groups at baseline when covariates were included in the analyses (Table 2.3). 
Prediabetic men weighed more than normoglycemic men. 
Association between Development of Prediabetes and Type 2 Diabetes and Changes in 
Body Composition 
Changes in body composition for the six glycemic groups are shown in Figures 2.2 
and 2.3. There were differences among men who developed prediabetes or T2D and men 
who remained normoglycemic regarding the annual change in TB and appendicular LM. 
Among men who were normoglycemic at baseline, those who progressed to prediabetic 
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lost more TB and appendicular LM than those who remained normoglycemic (Figure 2.3). 
Normoglycemic or prediabetic men who developed T2D also had greater losses in TB and 
appendicular LM than men who remained normoglycemic (Figure 2.3).  
Changes in Body Composition among Prediabetic Men Depending on Reversion to 
Normoglycemia 
There were no differences in the FM or LM between prediabetic men who remained 
prediabetic and those that reverted to normoglycemia (Figures 2.2 and 2.3). In general, 
prediabetic men who reverted to normoglycemia had negative changes in FM, whereas 
men who remained prediabetic had positive changes. 
Changes in Body Composition among Type 2 Diabetic Men  
Men who were T2D at baseline had greater gains in TB FM (Figure 2.2) and greater 
losses in TB and appendicular LM (Figure 2.3) than men who remained normoglycemic 
over the three-year follow-up.  
Discussion 
This is the first prospective population-based cohort study investigating the association 
of baseline glycemic status and changes in glycemic status over time with changes in TB, 
trunk, and appendicular FM and LM. Consequently, the findings of prior observational 
longitudinal studies cannot be compared to our findings. The findings of the current study 
indicate that there were no baseline differences among glycemic groups in TB, trunk, or 
appendicular FM and LM. Normoglycemic men who developed prediabetes or T2D had 
greater losses in TB and appendicular LM than men who remained normoglycemic. Men 
who had T2D throughout the study period had greater gains in TB FM, and greater losses 
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in TB and appendicular LM, than men who were normoglycemic throughout the study. No 
differences were observed in changes in weight or body composition measures among 
prediabetic men who reverted to normoglycemia compared to those who remained 
prediabetic. 
Contrary to our first hypothesis, we did not find differences in TB and regional FM 
and LM at baseline among the glycemic groups. The present study differs from other 
studies [6–8,10,22,23] due to the adjustment for covariates and inclusion of other body 
composition compartments (e.g., when determining whether TB FM was associated with 
glycemic status, TB LM was included in the statistical model). The inclusion of these 
covariates resulted in the relationships becoming non-significant.  
Consistent with our hypothesis, normoglycemic men who developed prediabetes or 
T2D had greater losses in TB and appendicular LM than men who remained 
normoglycemic, but we found no association with changes in FM. A positive association 
between glucose concentrations and intermuscular adipose tissue has been reported [24], 
and it has been suggested that hyperglycemia stimulates the differentiation of mesenchymal 
stem cells derived from adipose and muscle tissues into adipocytes by activating the protein 
kinase C β pathway [25]. Other studies also have reported an association between 
hyperglycemia and reduced TB and appendicular LM in men [10]. The underlying 
mechanisms of the decline in LM may include elevated circulating concentrations of 
inflammatory markers and oxidative stress. Biomarkers of inflammation, tumor necrosis 
factor alpha, and C-reactive protein stimulate the loss of skeletal muscle through the 
activation of nuclear factor kappa B [26] and the inhibition of protein synthesis [27]. 
Oxidative stress contributes to a catabolic and anabolic imbalance in skeletal muscle, 
59 
 
mitochondrial damage, and muscle atrophy and apoptosis [28]. These findings indicate that 
elevated inflammation markers in the presence of oxidative stress in prediabetic and T2D 
men can induce the loss of TB and appendicular LM. The present findings from the study 
support these reports.  
The association of changes in prediabetes status over time with changes in body 
composition by compartments have not been previously investigated. A few prospective 
studies have examined changes in TB and appendicular FM and LM in prediabetic 
individuals compared to normoglycemic controls. Our findings are similar to other studies 
reporting no difference in longitudinal changes in TB and lower extremity LM between 
individuals with and without prediabetes [14,16,29]. On the contrary, others have reported 
a loss in TB FM and appendicular LM that was greater in prediabetics compared to their 
normoglycemic counterparts [14,29].  
In addition to greater gains in TB FM among men with T2D than among 
normoglycemic men, we found a significant loss in TB and appendicular LM among men 
who either had T2D at baseline or developed T2D during the study compared to men who 
remained normoglycemic. By contrast, Park et al. [15] reported no differences in 
longitudinal changes in TB and appendicular FM and LM between older adults with 
normoglycemia and those diagnosed T2D. Our findings are consistent with longitudinal 
studies that have found T2D men gained TB FM and lost TB and appendicular LM [12–
14]. The mechanism for fat gain and muscle loss may stem from insulin resistance in T2D. 
An excessive influx of free fatty acids into the systemic circulation resulting from the 
adipose tissue contributes to insulin resistance by increasing fat accumulation in the liver 
leading to decreased insulin clearance, and increasing fat accumulation in skeletal muscle 
60 
 
by impairing glucose transport, decreasing muscle protein synthesis, and inducing muscle 
protein breakdown, leading to a reduced muscle surface area and insulin signaling [30, 31]. 
The strengths of our study include the first prospective population-based study of the 
association between changes in glycemic status and changes in TB and regional body 
composition measured by DXA, our low dropout rate, and our statistical adjustment for the 
same body composition compartments. Our study has several limitations. The present 
study included predominantly white men, and our findings may not be generalizable to 
women or other races. The majority of the men were farmers who may have different 
activity patterns and dietary intake than non-farmers, which may influence the relationship 
between dysglycemia and body composition. However, a study conducted on a 
representative sample of the United States (U.S.) population reported a similar association 
between dysglycemia and reduced lean mass [10]. Another limitation is the sample size of 
some of the glycemic categories. We did not observe differences between those men who 
were prediabetic at baseline and remained prediabetic, or reverted to normoglycemia as we 
hypothesized. It is likely that our sample size (n = 19 and 25, respectively) was too small. 
Based on the observed means and standard deviations in changes in TB FM, we estimate 
that 72 men per group would be needed (α = 0.05, β = 0.20). Despite the small sample size 
in some categories, we did observe other differences that we hypothesized, including 
differences in changes in TB and appendicular LM between normoglycemic men who 
developed prediabetes or T2D and those who remained normoglycemic throughout the 
study. We relied on participants’ recall of diagnosis of T2D, antidiabetic medication usage, 
dietary intake, and physical activity. A self-reported diagnosis of T2D or the use of 
antidiabetic medication can lead to misclassification due to recall or reporting errors. 
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Dietary and physical activity recalls may result in overestimation or underestimation. 
However, dietary intake and physical activity assessments were performed quarterly to 
consider seasonality. The 24-h diet recall [32] and PPAQ [19] are valid measures of dietary 
intake and physical activity in adults. Although this was a longitudinal study, given the 
period of time between measurements (three years), it is not possible to determine whether 
changes in glycemic status preceded changes in body composition or vice versa. Future 
studies should be over longer periods of time with more frequent measures of glycemic 
status and body composition in order to determine which factor comes first: dysglycemia 
or body composition changes. Only one fasting or non-fasting blood glucose measurement 
per visit was obtained for defining prediabetes and T2D. Although the American Diabetes 
Association recommends different criteria for screening for prediabetes and T2D using 
glycated hemoglobin, fasting blood glucose, and two-hour plasma glucose after an oral 
glucose tolerance test [21], numerous studies have reported that using two-hour plasma 
glucose test detects more cases of prediabetes and diabetes than using glycated hemoglobin 
or a fasting blood glucose test [33–38]; thus, we might have missed men with prediabetes 
and T2D using only one fasting blood glucose measurement, which would have made it 
more difficult to identify group differences in changes in body composition. 
Conclusion 
In conclusion, (1) there were no differences among glycemic groups in baseline TB 
and regional distribution of FM and LM; (2) men who were normoglycemic at baseline 
and developed prediabetes or T2D had greater losses in TB and appendicular LM than men 
who remained normoglycemic; (3) there were no differences in changes in body weight or 
composition among men who were prediabetic at baseline and remained prediabetic 
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compared to those who reverted back to normoglycemia; and (4) men who had T2D at 
baseline had greater gains in TB FM and greater losses in TB and appendicular LM than 
normoglycemic men. These findings add to a growing body of literature on the associations 
between changes in glycemic status and body composition. 
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Table 2.1. Baseline characteristics of the 430 men from the South Dakota Rural 
Bone Health Study cohort. NH: non-Hutterite. 
 
Normogly
cemic 
Pre-diabetic T2D p-Value 1 
Participants (n) 358 51 21  
Demographics     
  Age (years) 41.6 ± 0.6 a 45.8 ± 1.7 53.0 ± 2.6 a <0.001 
  Population Group (%)    0.001 
    Hutterite (n = 161) 73.3 18.0 8.7  
    NH Rural (n = 160) 89.3 8.8 1.9  
    NH Non-rural (n = 109) 89.0 7.3 3.7  
  Ever Married (%) 81.3 92.2 95.2 0.06 
Anthropometrics     
  Height (cm) 177.9 ± 0.4 177.9 ± 0.9 174.3 ± 1.5 0.06 
  Weight (kg) 91.1 ± 0.8 a 98.5 ± 2.1 a 95.9 ± 3.3 0.003 
Lifestyle Variables     
  Smokers (%) 33.2 24.0 38.1 0.43 
  BP Meds (%) 8.7 23.5 47.6 <0.001 
  % Time in MVPA 2 21.8 ± 0.5 23.1 ± 1.4 19.3 ± 2.1 0.32 
Daily Macronutrient Intake 2    
  Total energy (kcal) 2373 ± 33 2218 ± 87 2060 ± 135 0.03 3 
  Carbohydrate (g) 265 ± 5 ab 224 ± 12 b 202 ± 19 a <0.001 
  Fat (g) 97 ± 2 98 ± 4 90 ± 7 0.55 
  Protein (g) 105 ± 2 102 ± 4 102 ± 7 0.80 
Values are means ± sem or n (percentages). 1 Significance based on ANOVA for continuous variables and 
Fisher’s exact test for categorical variables; means with similar superscripts are different using a post hoc 
Tukey test. 2 Physical activity levels and nutrient intakes at baseline were the average of the baseline, 3-and 
6-month recalls. 3No means differed by post-hoc Tukey test for multiple comparisons. Abbreviations: T2D, 
type 2 diabetic; NH, non-Hutterite; BP Meds, hypertensive medications; MVPA, moderate-plus-vigorous 
physical activity. 
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Table 2.2. Anthropometrics, activity levels, and diet intake of the 411 men from the South Dakota Rural Bone Health 
Study cohort, according to glycemic categories after three years of follow-up. 
Baseline: Normoglycemic Pre-diabetic 
Normoglyce
mic or Pre-
diabetic 
T2D  
Follow-Up: Normoglycemic Pre-diabetic 
Normoglyce
mic 
Pre-diabetic T2D T2D 
p-Value 
1 
Participants (n) 272 65 25 19 12 18  
Baseline Age (years) 41.0 ± 0.7 ab 42.6 ± 1.5 c 43.9 ± 2.6 47.1 ± 2.3 51.9 ± 2.3 b 53.0 ± 2.2 ac <0.001 
Baseline Height (cm) 177.9 ± 0.4 177.0 ± 0.8 179.4 ± 1.0 176.9 ± 2.0 175.3 ± 1.7 175.1 ± 1.7 0.17 
Weight (kg)        
  Baseline 90.3 ± 0.9 ‡ 92.5 ± 2.0 96.1 ± 3.3 98.8 ± 3.9 100.4 ± 4.1 96.0 ± 3.1 0.01 3 
  Follow-Up 91.5 ± 0.9 93.3 ± 2.0 95.2 ± 3.4 100.1 ± 4.3 98.3 ± 4.0 96.0 ± 3.3 0.08 
% Time MVPA 2        
  Baseline 21.0 ± 0.6 ‡ 23.7 ± 1.2 22.6 ± 1.7 24.4 ± 2.3 26.2 ± 3.0  19.8 ± 2.1 0.11 
  Follow-Up 22.5 ± 0.6 22.1 ± 1.1 19.9 ± 1.6 21.9 ± 2.1 24.5 ± 2.5 22.8 ± 2.4 0.77 
Daily Intake 2       
  Total Energy (kcal)        
    Baseline 2344 ± 38 2435 ± 75 2284 ± 130 2140 ± 106 2248 ± 183 2067 ± 108 0.18 
    Follow-Up 2382 ± 38 a 2386 ± 81 b 2268 ± 102 2211 ± 95 2176 ± 189 1898 ± 132 ab 0.02 
   Carbohydrate (g)        
    Baseline 263 ± 5 a 268 ± 11 239 ± 17 208 ± 14 ‡ 233 ± 21 204 ± 15 a 0.003 
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    Follow-Up 265 ± 5 a 267 ± 13 b 248 ± 16 232 ± 14 208 ± 19 186 ± 16 ab 0.001 
  Fat (g)        
    Baseline 95 ± 2 102 ± 4 101 ± 7 94 ± 6 94 ± 10 91 ± 8 0.57 
    Follow-Up 101 ± 2 ‡ 100 ± 3 95 ± 5 98 ± 6 99 ± 11 90 ± 8 0.75 
  Protein (g)        
    Baseline 103 ± 2 107 ± 4 105 ± 7 96 ± 5 101 ± 11 101 ± 6 0.79 
    Follow-Up 104 ± 2 106 ± 3 105 ± 5 98 ± 5 107 ± 11 93 ± 8 0.50 
Values are unadjusted means ± sem or n (percentages). ‡ Significant change from baseline to follow-up based on paired t-test. 1 Significance 
among glycemic categories based on ANOVA for continuous variables and Fisher’s exact test for categorical variables; means with similar 
superscripts are different using a post hoc Tukey test. 2 Physical activity (PA) levels and nutrient intakes at baseline were the averages of the 
baseline, three-month, and six-month recalls, and at follow-up were the averages of 30-month, 33-month, and 36-month recalls. 3 No means 
differed by post hoc Tukey test for multiple comparisons. Abbreviations: T2D, type 2 diabetic; MVPA, moderate-plus-vigorous physical 
activity. 
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Table 2.3. Total body and regional body composition in the 430 men from the 
South Dakota Rural Bone Health Study cohort, according to glycemic status at 
baseline. 
 Normoglycemic Pre-diabetic T2D p-Value 1    
Participants (n) 358 51 21  
Body Weight (kg)     
  Unadjusted Model 91.1 ± 0.8 a 98.5 ± 2.1 a 95.9 ± 3.3 0.003 
  Basic Model 2 91.0 ± 0.8 a 97.0 ± 3.2 a 95.9 ± 3.2 0.01 
Fat Mass (kg)     
 Total Body     
   Unadjusted Model 22.1 ± 0.5 ab 26.4 ± 1.2 b 26.7 ± 1.9 a 0.001 
   Full Model 3 22.6 ± 0.3 24.0 ± 0.9 23.3 ± 1.5 0.38 
 Trunk     
   Unadjusted Model 11.4 ± 0.3 ab 14.2 ± 0.8 b 15.1 ± 1.2 a <0.001 
   Full Model 3 11.8 ± 0.2 12.6 ± 0.5 11.8 ± 0.9 0.38 
 Appendicular     
   Unadjusted Model 9.6 ± 0.2 a 11.1 ± 0.5 a 10.4 ± 0.8 0.01 
   Full Model 3 9.7 ± 0.2 10.3 ± 0.4 10.1 ± 0.7 0.66 
Lean Mass (kg)     
 Total Body     
   Unadjusted Model 67.0 ± 0.4 69.9 ± 1.2 66.8 ± 1.8 0.07 
   Full Model 4 67.1 ± 0.3 67.9 ± 0.8 67.9 ± 1.2 0.56 
 Trunk     
   Unadjusted Model 32.7 ± 0.2 a 34.5 ± 0.6 a 34.1 ± 0.9 0.01 
   Full Model 4 32.7 ± 0.1 33.1 ± 0.4 33.8 ± 0.6 0.24 
 Appendicular     
   Unadjusted Model 30.5 ± 0.2 31.6 ± 0.6 a 28.9 ± 0.9 a 0.04 
   Full Model 4 30.5 ± 0.2 31.0 ± 0.4 30.3 ± 0.7 0.44 
Data are means and marginal means ± sem. 1 p-values are from multiple regression models. Means 
with similar superscripts are different using a post hoc contrast test. 2 Basic model adjusted for 
age, height, population group, percent time in moderate-plus-vigorous activity, and average daily 
calories. 3 Fat mass models included covariates in basic model plus lean mass of same 
compartment (total body, trunk, or appendicular). 4 Lean mass models included covariates in basic 
model plus fat mass of same compartment. Abbreviations: T2D, type 2 diabetic. 
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Figure 2.1. Flowchart of participants. Abbreviations: DXA, dual-energy X-ray 
absorptiometry; T2D, type 2 diabetic. Individuals who were unable to be 
categorized into glycemic groups were excluded. 
 
 
 
 
  
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Adjusted marginal means of annual change from baseline in total body 
(p = 0.02), trunk (p = 0.06), and appendicular (p = 0.06) fat mass according to 
categories of glycemic status during the three-year follow-up. Model included 
baseline age, height, population group, percent time in moderate-plus-vigorous 
activity, average caloric intake, baseline measures of fat and lean mass in the 
specific body compartment (total body, trunk, or appendicular), changes in 
percent time in moderate-plus-vigorous activity and average caloric intake, and 
annual change in lean mass of the same compartment. Means with similar 
superscripts are different using post hoc contrast tests based on hypotheses. 
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Figure 2.3. Adjusted marginal means of annual change from baseline in total body 
(p = 0.004), trunk (p = 0.24), and appendicular (p < 0.001) lean mass according to 
categories of glycemic status during the three-year follow-up. Model included 
baseline age, height, population group, percent time in moderate-plus-vigorous 
activity, average caloric intake, baseline measures of fat and lean mass in the 
specific body compartment (total body, trunk, or appendicular), changes in 
percent time in moderate-plus-vigorous activity and average caloric intake, and 
annual change in the fat mass of the same compartment. Means with similar 
superscripts are different using post hoc contrast tests based on hypotheses. 
  
70 
 
References 
1. Cowie, C.C.; Rust, K.F.; Ford, E.S.; Eberhardt, M.S.; Byrd-Holt, D.D.; Li, C.; 
Williams, D.E.; Gregg, E.W.; Bainbridge, K.E.; Saydah, S.H. Full accounting of 
diabetes and pre-diabetes in the US population in 1988–1994 and 2005–2006. 
Diabetes Care 2009, 32, 287–294. 
2. Centers for Disease Control and Prevention. National Diabetes Statistics Report: 
Estimates of Diabetes and its Burden in the United States, 2014; US Department of 
Health and Human Services: Atlanta, GA, USA, 2014. 
3. Centers for Disease Control and Prevention. Prediabetes: Could It Be You? Available 
online:http://www.cdc.gov/diabetes/pubs/images/prediabetes-inforgraphic.jpg 
(accessed on 12 July 2017). 
4. O’Brien, M.J.; Whitaker, R.C.; Yu, D.; Ackermann, R.T. The comparative efficacy of 
lifestyle intervention and metformin by educational attainment in the Diabetes 
Prevention Program. Prev Med 2015, 77, 125–130. 
5. Steeves, J.A.; Murphy, R.A.; Crainiceanu, C.M.; Zipunnikov, V.; Van Domelen, D.R.; 
Harris, T.B. Daily patterns of physical activity by type 2 diabetes definition: 
Comparing diabetes, prediabetes, and participants with normal glucose levels in 
NHANES 2003–2006. Prev Med Rep 2015, 2, 152–157. 
6. Rabijewski, M.; Papierska, L.; Piątkiewicz, P. The relationships between anabolic 
hormones and body composition in middle-aged and elderly men with prediabetes: A 
cross-sectional study. J Diabetes Res 2016, 2016, doi:10.1155/2016/1747261. 
71 
 
7. Heshka, S.; Ruggiero, A.; Bray, G.A.; Foreyt, J.; Kahn, S.E.; Lewis, C.E.; Saad, M.; 
Schwartz, A.V. Altered body composition in type 2 diabetes mellitus. Int J Obes 
(Lond) 2008, 32, 780–787. 
8. Azuma, K.; Heilbronn, L.K.; Albu, J.B.; Smith, S.R.; Ravussin, E.; Kelley, D.E. 
Adipose tissue distribution in relation to insulin resistance in type 2 diabetes mellitus. 
Am J Physiol Endocrinol Metab 2007, 293, E435–E442. 
9. Leenders, M.; Verdijk, L.B.; van der Hoeven, L.; Adam, J.J.; van Kranenburg, J.; 
Nilwik, R.; van Loon, L.J. Patients with type 2 diabetes show a greater decline in 
muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc 
2013, 14, 585–592. 
10. Kalyani, R.R.; Tra, Y.; Egan, J.; Ferrucci, L.; Brancati, F. Hyperglycemia is associated 
with relatively lower lean body mass in older adults. J Nutr Health Aging 2014, 18, 
737–743. 
11. Lee, C.G.; Boyko, E.J.; Strotmeyer, E.S.; Lewis, C.E.; Cawthon, P.M.; Hoffman, A.R.; 
Everson-Rose, S.A.; Barrett-Connor, E.; Orwoll, E.S. Association between insulin 
resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. 
J Am Geriatr Soc 2011, 59, 1217–1224. 
12. Pownall, H.J.; Bray, G.A.; Wagenknecht, L.E.; Walkup, M.P.; Heshka, S.; Hubbard, 
V.S.; Hill, J.; Kahn, S.E.; Nathan, D.M.; Schwartz, A.V. Changes in body composition 
over 8 years in a randomized trial of a lifestyle intervention: The Look Ahead Study. 
Obesity 2015, 23, 565–572. 
13. Pownall, H.J.; Schwartz, A.V.; Bray, G.A.; Berkowitz, R.I.; Lewis, C.E.; Boyko, E.J.; 
Jakicic, J.M.; Chen, H.; Heshka, S.; Gregg, E.W. Changes in regional body 
72 
 
composition over 8 years in a randomized lifestyle trial: The Look Ahead Study. 
Obesity 2016, 24, 1899–1905. 
14. Lee, C.G.; Boyko, E.J.; Barrett-Connor, E.; Miljkovic, I.; Hoffman, A.R.; Everson-
Rose, S.A.; Lewis, C.E.; Cawthon, P.M.; Strotmeyer, E.S.; Orwoll, E.S. Insulin 
sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care 
2011, 34, 2381–2386. 
15. Park, S.W.; Goodpaster, B.H.; Lee, J.S.; Kuller, L.H.; Boudreau, R.; De Rekeneire, 
N.; Harris, T.B.; Kritchevsky, S.; Tylavsky, F.A.; Nevitt, M. Excessive loss of skeletal 
muscle mass in older adults with type 2 diabetes. Diabetes Care 2009, 32, 1993–1997. 
16. Kalyani, R.R.; Metter, E.J.; Egan, J.; Golden, S.H.; Ferrucci, L. Hyperglycemia 
predicts persistently lower muscle strength with aging. Diabetes Care 2015, 38, 82–
90. 
17. Specker, B.; Binkley, T.; Fahrenwald, N. Rural versus nonrural differences in BMC, 
volumetric BMD, and bone size: A population-based cross-sectional study. Bone 2004, 
35, 1389–1398. 
18. Paffenbarger, R.S.; Wing, A.L.; Hyde, R.T. Physical activity as an index of heart 
attack risk in college alumni. Am J Epidemiol 1978, 108, 161–175. 
19. Simpson, K.; Parker, B.; Capizzi, J.; Thompson, P.; Clarkson, P.; Freedson, P.; 
Pescatello, L.S. Validity and reliability question 8 of the Paffenbarger physical activity 
questionnaire among healthy adults. J Phys Act Health 2015, 12, 116–123. 
20. Samra, H.A.; Beare, T.; Specker, B. Pedometer readings and self-reported walking 
distances in a rural Hutterite population. J Rural Health 2008, 24, 99–100. 
73 
 
21. American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. In 
standards of medical care in diabetes—2015. Diabetes Care 2015, 38, S8–S16. 
22. Kim, T.N.; Park, M.S.; Yang, S.J.; Yoo, H.J.; Kang, H.J.; Song, W.; Seo, J.A.; Kim, 
S.G.; Kim, N.H.; Baik, S.H. Prevalence and determinant factors of sarcopenia in 
patients with type 2 diabetes: The Korean Sarcopenic Obesity Study (KSOS). Diabetes 
Care 2010, 33, 1497–1499. 
23. Julian, V.; Blondel, R.; Pereira, B.; Thivel, D.; Boirie, Y.; Duclos, M. Body 
composition is altered in pre-diabetic patients with impaired fasting glucose tolerance: 
Results from the NHANES survey. J Clin Med Res 2017, 9, 917–925. 
24. Yim, J.; Heshka, S.; Albu, J.; Heymsfield, S.; Kuznia, P.; Harris, T.; Gallagher, D. 
Intermuscular adipose tissue rivals visceral adipose tissue in independent associations 
with cardiovascular risk. Int J Obes (Lond) 2007, 31, 1400–1405. 
25. Aguiari, P.; Leo, S.; Zavan, B.; Vindigni, V.; Rimessi, A.; Bianchi, K.; Franzin, C.; 
Cortivo, R.; Rossato, M.; Vettor, R. High glucose induces adipogenic differentiation 
of muscle-derived stem cells. Proc Natl Acad Sci USA 2008, 105, 1226–1231. 
26. Li, Y.-P.; Reid, M.B. Nf-κb mediates the protein loss induced by TNF-α in 
differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 
2000, 279, R1165–R1170. 
27. Wåhlin-Larsson, B.; Wilkinson, D.J.; Strandberg, E.; Hosford-Donovan, A.; Atherton, 
P.J.; Kadi, F. Mechanistic links underlying the impact of c-reactive protein on muscle 
mass in elderly. Cell Physiol Biochem 2017, 44, 267–278. 
28. Bianchi, L.; Volpato, S. Muscle dysfunction in type 2 diabetes: A major threat to 
patient’s mobility and independence. Acta Diabetol 2016, 53, 879–889. 
74 
 
29. Piaggi, P.; Thearle, M.S.; Bogardus, C.; Krakoff, J. Fasting hyperglycemia predicts 
lower rates of weight gain by increased energy expenditure and fat oxidation rate. J 
Clin Endocrinol Metab 2015, 100, 1078–1087. 
30. Frayn, K.N. Visceral fat and insulin resistance—causative or correlative? Br J Nutr 
2000, 83, S71–S77. 
Brøns, C.; Grunnet, L.G. Mechanisms in endocrinology: Skeletal muscle lipotoxicity 
in insulin      resistance and type 2 diabetes: A causal mechanism or an innocent 
bystander? Eur J Endocrinol 2017, 176, R67–R78. 
31. Conway, J.M.; Ingwersen, L.A.; Moshfegh, A.J. Accuracy of dietary recall using the 
USDA five-step multiple-pass method in men: An observational validation study. J 
Am Diet Assoc 2004, 104, 595–603. 
32. Menke, A.; Casagrande, S.; Geiss, L.; Cowie, C.C. Prevalence of and trends in diabetes 
among adults in the United States, 1988–2012. JAMA 2015, 314, 1021–1029. 
33. Menke, A.; Rust, K.F.; Cowie, C.C. Diabetes based on 2-h plasma glucose among 
those classified as having prediabetes based on fasting plasma glucose or A1c. Diab 
Vasc Dis Res 2018, 15, 46–54. 
34. Cowie, C.C.; Rust, K.F.; Byrd-Holt, D.D.; Eberhardt, M.S.; Flegal, K.M.; Engelgau, 
M.M.; Saydah, S.H.; Williams, D.E.; Geiss, L.S.; Gregg, E.W. Prevalence of diabetes 
and impaired fasting glucose in adults in the US population. Diabetes Care 2006, 29, 
1263–1268. 
35. Cowie, C.C.; Rust, K.F.; Byrd-Holt, D.D.; Gregg, E.W.; Ford, E.S.; Geiss, L.S.; 
Bainbridge, K.E.; Fradkin, J.E. Prevalence of diabetes and high risk for diabetes using 
A1c criteria in the US population in 1988–2006. Diabetes Care 2010, 33, 562–568. 
75 
 
36. DECODE Study Group. Age-and sex-specific prevalences of diabetes and impaired 
glucose regulation in 13 European cohorts1. Diabetes Care 2003, 26, 61–69. 
37. NCD Risk Factor Collaboration. Effects of diabetes definition on global surveillance 
of diabetes prevalence and diagnosis: A pooled analysis of 96 population-based studies 
with 331 288 participants. Lancet Diabetes Endocrinol 2015, 3, 624–637. 
  
76 
 
 
CHAPTER 3: Impacts of Cross-Sectional and Longitudinal Changes in Glycemic 
Status in Men Aged 20-66 Years on Bone: A Population-based Cohort Study 
Khaleal Almusaylim, Maggie Minett, Teresa Binkley, Tianna Beare, Bonny Specker, 
Ethel Austin Martin Program in Human Nutrition, South Dakota State University, 
Brookings, SD, USA 
 
 
 
 
  
77 
 
Abstract 
Background: The effect of various categories of glycemic status on bone mass and 
density remains unknown. The aim of the current study was to determine the effect of 
cross-sectional and longitudinal changes in glycemic status on bone mineral content 
(BMC) and areal bone mineral density (aBMD) in men, aged 20-66 y, from the South 
Dakota Rural Bone Health study.  
Methods: Prospective study of 430 men (age: 42.7 ± 0.6 [SE]) with dual-energy x-ray 
absorptiometry-derived indices of body composition and regional bone measures 
obtained at baseline and three-year. Pre-diabetes was defined by fasting plasma glucose 
100 to 125 mg/dL and type 2 diabetes (T2D) was determined by: self-reported T2D, 
current use of anti-diabetic drug (insulin/oral hypoglycemic agents), or a fasting or non-
fasting serum glucose concentration (≥126 and ≥200 mg/dL, respectively) at baseline and 
follow-up. Multivariate analysis was used to estimate marginal means of baseline and 
annualized percent change in bone outcomes among different categories of glycemic 
status controlling for age, age2, height, population group, and total body fat and lean 
mass.  
Results: At baseline, femoral neck (FN) BMC and hip and FN aBMD were greater in 
pre-diabetic and T2D men than normoglycemic men, but differences did not remain 
significant after controlling for body composition.  Relationship between hip aBMD and 
lean mass was attenuated in pre-diabetic men vs. normoglycemic and T2D men (group-
by-lean interaction, p = 0.004); similar results were observed with hip BMC and spine 
aBMD.  FN aBMD loss was greater in T2D men and men who were normoglycemic/pre-
diabetic at baseline and developed T2D compared to normoglycemic men who developed 
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pre-diabetes (all, p ≤ 0.05).  Normoglycemic/pre-diabetic men who progressed to T2D 
had greater loss in FN aBMD than men who were pre-diabetic and regressed to 
normoglycemia (Figure 2). 
Conclusion: Glycemic status has deleterious effects on bone and may modify the 
relationships between bone and lean mass.  
Keywords: pre-diabetes; type 2 diabetes; areal bone mineral density; bone mineral 
content, aging   
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Introduction  
Osteoporosis, pre-diabetes, and type 2 diabetes (T2D) are major public health issues 
in the United States [1,2]. The 2005-2010 National Health and Nutrition Examination 
Survey reported that the prevalence of osteoporosis in men aged ≥50 years was 4.3% 
(about 2 million men). Osteoporosis increases the risk of skeletal fractures, and the 
estimated economic burden of osteoporotic fractures in adult men in the United States 
aged ≥50 years was $4.1 billion in 2005 and is projected to increase by 27% in 2025 [1]. 
Pre-diabetes and diabetes also affect a large percent of U.S. adults aged 20 years or older 
(37.2% and 10.4%, respectively), with approximately 86 million adults with pre-diabetes 
and 30.4 million adults with diabetes in 2012. The estimated national total cost of pre-
diabetes and diabetes in 2012 was $44 billion and $277 billion, respectively [2]. Fracture 
risk has been reported to be elevated in individuals with T2D [3,4].      
Numerous cross-sectional and case-control studies have evaluated the association 
between pre-diabetes or T2D and bone health with inconsistent findings. Studies among 
men with pre-diabetes or T2D find high [5-7], low [8-10], or similar BMC or aBMD at 
multiple skeletal sites compared to men without diabetes [5,11-14]. A limited number of 
longitudinal studies examining bone changes have been conducted in men with various 
categories of glucose tolerance at baseline. Three prospective observational studies found 
similar longitudinal changes in femoral neck (FN) BMC [8] and FN and hip aBMD 
[15,16] among pre-diabetic, T2D, and normoglycemic men, whereas an increased spine 
aBMD was observed in men with T2D [16]. The authors proposed that the observed 
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increase in spine aBMD might be attributed to interference of aortic calcification on spine 
aBMD measurements and degenerative spinal changes related to aging [16].  
Bone measures are associated with body mass and the majority of observational 
studies adjust for either body mass index (BMI) or body weight [5,7-9].  However, these 
studies fail to consider the effect of body composition on bone mineral status. Total lean 
mass is correlated with both insulin levels [17] and bone measures in normoglycemic and 
T2D men [6,18-20]. Total lean mass directly affects bone mass through both gravitational 
and muscle loads [21] and indirectly mediates the effect of insulin on bone health [17]. 
There is some controversy, however, on the influence of fat mass on bone [6,20,22]. 
Cross-sectional studies find a negative association between fat mass and FN aBMD [22], 
but a positive correlation with hip aBMD in T2D men [6] and normoglycemic men 
[19,20]. Increased fat mass also is associated with hyperinsulinemia that stimulates 
secretion of peptides (insulin, preptin, and amylin), which in turn, may increase bone 
mass by inhibiting osteoclastogenesis and enhancing osteoblastogenesis [23]. However, 
elevation of pro-inflammatory cytokines is observed in pre-diabetic and T2D individuals 
[24,25] and is associated with increased bone resorption [26]. Since body composition 
may differ between men with and without pre-diabetes or T2D, it is important to control 
for lean mass and fat mass individually when investigating whether or not there is an 
association between bone health and glycemic status.  
No studies have evaluated changes in BMC and aBMD in men who develop pre-
diabetes, revert from pre-diabetic to the normoglycemic state, or convert from pre-
diabetes to T2D. To the best of our knowledge, this is the first study to report the effect of 
changes in glycemic status on longitudinal changes in BMC and aBMD.   
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The objectives of this study were to determine both cross-sectional and longitudinal 
relationships between bone measures (BMC and aBMD) and glycemic status in men and 
the role of differences in body composition on these relationships. The South Dakota 
Rural Bone Health (SDRBH) study is a population-based cohort study designed to 
identify lifestyle risk factors affecting bone and body composition. Data from this 
population-based longitudinal study were used to test the following hypotheses:  (1) 
individuals with pre-diabetes or T2D at baseline would have higher BMC and aBMD 
compared to normoglycemic individuals, but these differences would not remain 
significant when controlling for differences in body composition, (2) normoglycemic or 
pre-diabetic men who developed T2D would have similar changes in BMC and aBMD as 
men who remained normoglycemic after adjusting for differences in body composition, 
and (3) among men with pre-diabetes, the change in BMC and aBMD would differ 
depending on whether they developed T2D or reverted to normoglycemic state.  Men 
developing T2D would have decreases in BMC and aBMD compared to men who remain 
pre-diabetic after adjusting for body composition, while those reverting to a 
normoglycemic state would maintain or increase their BMC and aBMD.  
Methods 
Study population  
From 2000 to 2004, 1,271 participants were recruited from eight counties in eastern 
South Dakota as previously described [27]. Of these participants, 544 were men aged 20 
to 66 years. Among those men, 410 men farmed at least 75% of their lives (rural), and 
134 men never lived on an active farm (non-rural). The rural population was divided into 
Hutterites and non-Hutterites. A Hutterite was a participant of Hutterite descent who 
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resided on a Hutterite colony. Hutterites are an Anabaptist religious group who believes 
in isolated communal living and self-sufficiency through an agriculturally advanced 
lifestyle. Non-Hutterites were randomly recruited from the eight-county region as 
described elsewhere [27]. 
Due to possible effects on bone, individuals with chronic use (>six months) of 
immunosuppressants, anticonvulsants, or steroids or a diagnosis of type 1 diabetes 
mellitus at baseline were excluded. For the current analyses, we excluded individuals 
with missing information for blood glucose or bone measurements at either the baseline 
or follow-up visit as well as individuals who withdrew from the study (Figure. 1). The 
study was approved by the South Dakota State University Institutional Review Board, 
and informed consent was obtained. 
Body composition and bone measurements 
Body composition of the total body and bone measurements of the left hip and spine 
were measured at baseline and 36 months using dual-energy x-ray absorptiometry (DXA) 
while wearing light clothing without shoes (Discovery Software Version 12.01, Hologic 
INC., Bedford, MA). All scans were analyzed by one ISCD-certified technician.  Scan 
results were deleted for obese participants with an equivalent epoxy thickness greater 
than 12 inches as determined by the Hologic software and per manufacturer 
recommendations (16 men: 7 Hutterite, 4 rural, 5 non-rural).  Quality control of the 
scanner was assessed using the Hologic spine phantom. Quantification procedures 
outlined by Orwoll et al. [28] were used to monitor and adjust results for longitudinal 
fluctuations in scanner performance. Our coefficients of variation assessed in 15 adults (1 
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male) using triplicate scans with repositioning between each scan were <1.5% for total 
body lean and fat mass and <2% for hip and spine BMC and BA [29].  
Anthropometric measurements  
Body height and weight were measured in lightweight clothes without shoes using 
calibrated stadiometer and scale. Standing height was measured in duplicate to the 
nearest 0.5 cm in using a Seca stadiometer (Chino, CA). A third measurement was taken 
if the discrepancy between the duplicate height measurements was more than 0.5 cm. 
Weight was measured to the nearest 0.1 kg with a Seca digital scale (Model 770, Chino, 
CA). BMI was calculated as weight (kg) divided by height (m2).  
Ascertainment of pre-diabetes and type 2 diabetes 
       According to the American Diabetes Association, individuals with fasting plasma 
glucose of 100 mg/dL to 125 mg/dL are classified as having pre-diabetes [30]. T2D was 
determined by one of the following criteria: self-reported T2D, current use of an anti-
diabetic drug (insulin or oral hypoglycemic agents), or a fasting plasma glucose 
concentration ≥126 mg/dL or a non-fasting plasma glucose concentration ≥200 mg/dL 
[30]. The same criteria for the diagnosis of pre-diabetes and T2D were applied at both the 
baseline and three-year visits. Glucose measurements were made in the field from a 
sample of venous whole blood (EDAT) using an Accu-Check Advantage glucometer 
(Roche Diagnostics, Indianapolis, IN).  Based on these criteria, 51 men were classified as 
pre-diabetic at baseline and 48 of them had follow-up data. Of these 48, 19 remained pre-
diabetic, 25 reverted to normoglycemic, and 4 converted to T2D at three-year visit.  Of 
the 21 men classified as T2D at baseline, 14 self-reported a diagnosis of T2D and 7 were 
84 
 
classified as T2D based on their blood sugar results.  Of these 21, 18 were included in the 
follow-up analysis with 4 self-reporting a diagnosis of T2D, 11 reported taking anti-
diabetic prescribed drugs, and 3 were classified as T2D based on their blood sugar 
results.  
Statistical analysis  
Differences in baseline characteristics among different categories of glucose 
intolerance were tested using one-way analysis of variance with Tukey HSD post hoc 
comparison of means for continuous variables and chi-square test for categorical 
variables. Glucose intolerance was entered in linear regression as an ordinal variable with 
normoglycemic, pre-diabetic and T2D coded as 0, 1 and 2 to test for a linear trend and 
was also considered a categorical variable when estimating marginal means for 
annualized percent changes in outcome measures. Differences in marginal means among 
glucose intolerance groups were evaluated using pairwise contrasts. Three regression 
models were developed for each bone outcome. Model 1 did not include any covariates 
and was based on a simple analysis of variance.  Model 2 included age, age2 (to account 
for the non-linear effect of age on bone outcomes), height, and population group as 
covariates.  Model 3 included covariates listed in Model 2 along with total body fat and 
lean mass to determine whether there were differences in bone measures associated with 
glycemic status independent of body composition. For models investigating annualized 
percent change in bone measures, baseline bone and body composition measures, and 
annual percent changes in total body fat and lean mass were added to the Model 3. 
Glycemic status might moderate the relationship between baseline fat or lean mass on 
baseline bone parameters and we tested the glycemic group-by-fat mass and glycemic 
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group-by-lean mass interactions.  All analyses were performed using JMP software 
(version 13, SAS Institute, Cary, NC).  Data are presented as means ± standard error (SE) 
for quantitative variables and percentages for categorical variables, and the statistical 
significance level was set at p ≤ 0.05.     
Results 
Baseline characteristics  
 Of the 544 men enrolled in the SDRBH study, 35 were missing glucose or body 
composition measurements at baseline and another 79 either withdrew prior to 36 months 
(n=45 [8.3% dropout rate]) or were missing blood glucose measurements at 36 months 
(n=34) (Figure 2.1).  Of the 430 men who could be categorized into groups of different 
glycemic status at baseline, 19 did not have total body DXA measurements at 36 months 
resulting in 411 men for whom there were both baseline and follow-up results. Among 
the men participating in this study, 83.2% were normoglycemic, 11.9% were pre-diabetic 
and 4.9% had T2D at baseline. Of the 358 men who were normoglycemic at baseline, 345 
were included in the follow-up analyses.  Of the 345, 272 (78.8%) maintained a constant 
normoglycemic state, 65 (18.8%) developed pre-diabetes, and 8 (2.3%) progressed to 
T2D. Among the 48 men who were pre-diabetic at baseline and included in the follow-up 
analyses, 19 (39.6%) remained pre-diabetic, 25 (52.1%) reverted to normoglycemia, and 
4 (8.3%) developed T2D.  
 At baseline, normoglycemic men were younger than men with T2D, had lower 
weight than pre-diabetic men, and had lower BMI and fat mass than both pre-diabetic and 
T2D men (Table 3.1).  Although aBMD Z-scores tended to be higher in men with T2D, 
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post hoc Tukey tests for multiple comparisons did not show any group differences.  
Hutterite men were more likely to have pre-diabetes or T2D than rural and non-rural men 
(Table 3.1).   
 There were significant baseline differences in age, weight, BMI, and fat mass among 
the six groups at follow-up analyses (Table 3.2).  Men who were normoglycemic at 
baseline and remained normoglycemic were younger at baseline than T2D men or men 
who were normoglycemic or pre-diabetic at baseline and converted to T2D.  Men with 
T2D throughout the study were older than men who progressed from normoglycemia to 
pre-diabetes. Men who were normoglycemic throughout the study weighed less, had 
lower BMI, and less fat mass then both men who were pre-diabetic throughout the study 
and men who were either normoglycemic or pre-diabetic at baseline and progressed to 
T2D.  Additionally, men who were normoglycemic throughout the study had lower fat 
mass than men who had T2D throughout the study.    
Cross-sectional analysis  
Bone indices at baseline are summarized in Table 3.3.  Although the main effect of 
glycemic status on FN BMC and FN and hip aBMD was significant after adjusting for 
age, age2, height, and population group, there were no statistical differences among 
groups after adjusting for fat and lean mass.  
Longitudinal analysis  
The only significant difference among categories of glycemic status was the annual 
percent change in FN aBMD, which was only significant after adjusting for covariates in 
Models 2 and 3 (Figure 3.2, Supplementary Table 3.1). The loss of FN aBMD was 
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greater in T2D men and men who were normoglycemic or pre-diabetic at baseline and 
developed T2D compared to normoglycemic men who developed pre-diabetes.  
Normoglycemic or pre-diabetic men who progressed to T2D had greater loss in FN 
aBMD than men who were pre-diabetic and regressed to normoglycemia (Figure 3.2).  
Differences in unadjusted mean percent change in spine bone area among glycemic 
groups did not remain significant after controlling for covariates (Supplementary Table 
3.1). 
Moderating effects of fat and lean mass  
The moderating effect of glycemic status on the baseline relationships between bone 
outcomes and fat or lean mass were investigated using the glycemic group-by-fat mass 
and group-by-lean mass interactions. Glycemic status at baseline modified the 
relationship between hip aBMD and lean mass (group-by lean interaction, p = 0.004) 
with an expected positive correlation between hip aBMD and lean mass in the 
normoglycemic and T2D men, but a weaker relationship among pre-diabetic men (Figure 
3.3). Similar relationships were observed for hip BMC (group-by lean interaction, p = 
0.04) and spine aBMD (group-by-lean interaction, p = 0.03) (data not shown).   
Discussion 
We examined the influence of glycemic status at baseline and follow-up on bone 
health in a population-based study of men. We found, consistent with our first hypothesis, 
that there were significant differences in baseline FN BMC and hip and FN aBMD by 
glycemic status when controlling for age, age2, height, and populations group, but these 
differences did not remain significant after adjusting for fat and lean mass. We also found 
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that men who were normoglycemic or pre-diabetic at baseline and progressed to T2D had 
the greatest loss in FN aBMD followed by men who were diabetic throughout the study. 
Additionally, we showed that glycemic status at baseline modified the relationship 
between bone measures and lean mass.  
The impact of pre-diabetes and T2D on FN, hip, and spine BMC and aBMD in men 
remains controversial.  Our study provides further support for similar BMC and aBMD at 
multiple sites among men with and without pre-diabetes and T2D as previously described 
in cross-sectional studies [7,11-13], which contrasts to other findings [5,10]. We 
observed greater FN BMC and FN and hip aBMD among pre-diabetic and T2D men 
compared to normoglycemic men at baseline after controlling for age, height and 
population. However, when adjusting for fat mass and lean mass, these differences were 
no longer significant which is contrary to the findings of Strotmeyer et al. [6] who 
showed higher hip aBMD among older adults with T2D, independent of fat and lean 
mass. Strotmeyer et al. [6] observed an inverse relationship between hip aBMD and T2D 
duration, indicating that hip aBMD varied among T2D individuals with a long duration of 
disease. This may partially explain the inconsistency with our study, although we did not 
have information on duration of T2D among our participants.  Our findings indicate that 
given two groups of men of identical body composition, one with T2D and one without 
T2D, the group with T2D would have similar bone mass to the group without T2D.  It 
also suggests that the tendency toward higher aBMD Z-scores among T2D men is a result 
of differences in body composition and not T2D per se.    
Previous studies suggest that higher circulating concentrations of insulin, IGF-I, and 
sclerostin may explain the greater BMC and aBMD among pre-diabetics and diabetics 
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[31-34]. Insulin is anabolic to osteoblasts, which may contribute to differences in bone 
mass [31]. Insulin resistance or hyperinsulinemia, which is higher in individuals with pre-
diabetes and newly diagnosed T2D, induces the synthesis of IGF-I and inhibits the 
synthesis of IGF binding protein I in the liver, hereby increasing serum IGF-I 
concentrations into the circulatory system [32].  IGF-I stimulates bone formation by 
regulating osteoblast differentiation and proliferation and inducing synthesis of collagen 
to increase bone matrix production and bone mass [33,34]. Cutrim et al. [35] report that 
FN aBMD is positively associated with circulating IGF-I concentrations in T2D 
individuals. Sclerostin, expressed by osteocytes, is higher in pre-diabetic and T2D 
individuals due to its association with fasting glucose and glycated hemoglobin [36,37]. 
Sclerostin concentrations are positively associated with FN, hip and spine aBMD. Low 
bone turnover can potentially account for the correlation between sclerostin and aBMD 
[37].   
There is no epidemiological evidence for the role of glycemic status as a moderator 
of the impact of body composition on bone measures, and total body fat and lean mass 
may affect bone in individuals with pre-diabetes and T2D differently than in individuals 
with normoglycemia. As far as we know, this is the first study to report a moderating 
effect of different categories of glycemic status on the relationship between lean mass 
and bone health. Strong correlations between bone measures and lean mass have been 
reported previously [20], believed to be in response to the loads muscle contractions 
place on bone [21]. We observed a positive relationship between baseline total hip aBMD 
and lean mass, but this relationship was attenuated among men with pre-diabetes. The 
reason for this attenuation among men with pre-diabetes but not T2D is not known. There 
90 
 
is a positive association between hip aBMD and muscle strength, suggesting that muscle 
force or contraction exerts loads on bone [38], and perhaps a reduced muscle strength in 
pre-diabetes contributes to the lower hip aBMD among pre-diabetics compared to 
normoglycemic men that were observed with greater lean mass.  
Previous prospective observational studies have primarily examined the influence of 
pre-diabetes and T2D on FN bone loss. In contrast to earlier findings [15,16], T2D men 
had greater FN aBMD loss than men who became pre-diabetic. We believe that we are 
the first to report a greater loss in FN aBMD in men who were normoglycemic or pre-
diabetic at baseline and developed T2D compared to those who were pre-diabetic and 
reverted to normoglycemia. The association between FN aBMD loss and glycemic status 
was attenuated, but remained statistically significant, after adjustment for initial aBMD 
and annual percent changes in total fat and lean mass. Acute hyperglycemia is 
accompanied by elevation of pro-inflammatory cytokines in pre-diabetes and T2D [39-
41] that induce bone loss through stimulation of osteoclast differentiation and impaired 
bone formation [42]. Long-term exposure to hyperglycemia in T2D men may explain 
why men who were T2D throughout the study or developed T2D had greater loss of FN 
aBMD than men who developed pre-diabetes.  
Strengths of our population-based study include a high retention rate, a wide age 
range, evaluation of progression to pre-diabetes and regression to normoglycemia effects 
on bone health for the first time, and not only an examination of changes in bone 
measures across various categories of glycemic status, but an examination of interactions 
between glycemic status and body composition on bone mass and density. Our study has 
several limitations. First, the study population is predominately Caucasians, therefore; 
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our findings cannot be generalized to other racial groups. Second, we are unable to adjust 
for other covariates in our analysis that may affect aBMD, including insulin and pro-
inflammatory cytokine concentrations, the duration of pre-diabetes and T2D, or oral 
pharmacological therapy for T2D. Third, diagnosis of T2D and use of antidiabetic agents 
were based on self-report; thus, there was potential misclassification.  Finally, only one 
fasting or non-fasting glucose measurement was obtained at baseline and was used as a 
screening tool for identifying men with pre-diabetes and T2D. Several studies have 
reported that a 2-h plasma glucose test identifies more pre-diabetic and diabetic cases 
than a blood glucose test; therefore, we might have misclassified men with pre-diabetes 
or T2D as normoglycemic.      
Conclusion 
In this population-based cohort study of men aged 20 to 66 years, we found no effect 
of baseline glycemic status on bone measures after adjusting for differences total body fat 
mass and lean mass. However, the relationship between aBMD and lean mass varied by 
glycemic group.  Change in glycemic status at follow-up was associated with FN aBMD, 
with the greatest bone loss among men who developed T2D during the study or had T2D 
throughout the study.  These findings may elucidate an increased fracture risk in T2D and 
further studies are warranted to confirm our findings.      
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Table 3.1. Baseline characteristics by glycemic status. 
 Normoglycemia Pre-diabetes T2D p-Value 1 
Participants (n) 358 51 21  
Age (y) 41.6 ± 0.6a 45.8 ± 1.7 53.0 ± 2.6a <0.001 
Population group (%)    <0.001 
   Hutterite (n=161) 73.3 18.0 8.7  
   NH Rural (n=160) 89.3 8.8 1.9  
   NH Non-rural (n=109) 89.0 7.3 3.7  
Height (cm) 177.9 ± 0.4 177.9 ± 0.9 174.3 ± 1.5 0.06 
Weight (kg) 91.1 ± 0.8a 98.5 ± 2.1a 95.9 ± 3.3 0.003 
BMI (kg/m2) 28.8 ± 0.2ab 31.1 ± 0.6b 31.5 ± 1.0a <0.001 
Lean mass (kg) 67.0 ± 0.4 69.9 ± 1.2 66.8 ± 1.8 0.07 
Fat mass (kg) 22.1 ± 0.5ab 26.4 ± 1.2b 26.7 ± 1.9a <0.001 
aBMD Z-scores     
    Femoral neck 0.34 ± 0.05 0.63 ± 0.12 0.71 ± 0.19 0.022 
   Total hip 0.45 ± 0.05 0.75 ± 0.12 0.84 ± 0.19 0.012 
    Lumbar spine  0.17 ± 0.07 0.58 ± 0.19 0.76 ± 0.29 0.022 
        Values are means ± SE or frequency (percentages). Means with similar superscripts are different using a 
post hoc Tukey test for multiple comparisons. 1 P-values are based on ANOVA for continuous variables 
and chi-square test for categorical variables. 2 No difference between glucose status groups using a post hoc 
Tukey test for multiple comparisons. Abbreviations: T2D = type 2 diabetes; NH = non-Hutterite; BMI = 
body mass index; aBMD = areal bone mineral density.  
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Table 3.2. Baseline characteristics of participants by glycemic status at baseline and follow-up. 
Baseline: Normoglycemia Pre-diabetes 
Normoglycemia 
or Pre-diabetes 
T2D  
Follow-Up: 
Normoglycemia 
 
Pre-diabetes 
 
Normoglycemia 
 
Pre-diabetes 
 
T2D 
 
T2D 
 
p-Value 
1 
Participants (n) 272 65 25 19 12 18  
Baseline variables         
  Age (y) 41.0 ± 0.7ab 42.6 ± 1.5c 43.9 ± 2.4 47.1 ± 2.8 51.9 ± 3.5b 53.0 ± 2.8ac <0.001 
  Population group (%)      <0.0012 
    Hutterite (n=154) 50.7 22.1 8.4 7.1 4.6 7.1  
    NH Rural (n=151) 80.1 8.6 6.0 2.0 1.3 2.0  
    NH Non-rural (n=106) 68.9 17.0 2.8 4.7 2.8 3.8  
 Height (cm) 177.9 ± 0.4 177.0 ± 0.8 179.4 ± 1.3 176.9 ± 1.5 175.3 ± 1.9 175.1 ± 1.5 0.17 
 Weight (kg) 90.3 ± 0.9ab 92.5 ± 1.9 96.1 ± 3.0 98.8 ± 3.4b 100.4 ± 4.3a 96.0 ± 3.5 0.0134 
 BMI (kg/m2) 28.5 ± 0.3ab 29.5 ± 0.6 29.9 ± 0.9 31.6 ± 1.0b 32.7± 1.3a 31.4 ± 1.1 <0.001 
 Lean mass (kg) 66.6 ± 0.5 67.5 ± 1.0 69.2 ± 1.6 70.0 ± 1.9 70.3 ± 2.4 67.4 ± 1.9 0.22 
 Fat mass (kg) 21.6 ± 0.5abc 23.0 ± 1.1 24.7 ± 1.7 26.6 ± 2.0 c 28.2 ± 2.5 a 25.9 ± 2.0 b 0.00534 
 aBMD Z-scores        
   Femoral neck 0.31 ± 0.05 0.42 ± 0.11 0.79 ± 0.17 0.48 ± 0.20 0.69 ± 0.25 0.72 ± 0.21 0.043 
   Total hip 0.42 ± 0.05 0.57 ± 0.11 0.87 ± 0.17 0.62 ± 0.20 0.71 ± 0.25 0.86 ± 0.20 0.053 
   Lumbar spine5  0.14± 0.08 0.31 ± 0.16 0.44 ± 0.27 0.55 ± 0.30 0.51 ± 0.38 0.89 ± 0.31 0.16 
Values are means ± SE or percentages. 1 P-values are based on ANOVA for continuous variables and chi-square test for categorical variables. Means 
with similar superscripts are different using a post hoc Tukey test for multiple comparisons. 2 20% of cells have expected count less than 5. 3 No 
differences among glucose intolerance groups using a post hoc Tukey test for multiple comparisons. 4 No differences among glucose intolerance groups 
using a post hoc Tukey test for multiple comparisons; superscripts show differences based on contrasts. 5 Five fewer spine scans available than hip scans 
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at 36 months; four in the normo/normoglycemic group and one in the pre/prediabetes group. Number of hip scans given. Abbreviations: T2D = type 2 
diabetes; BMI = body mass index; aBMD = areal bone mineral density.
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Table 3.3. Baseline bone outcomes according to glycemic status. 
Values are unadjusted mean + SE. Superscripts show means that were different based on model 2 using 
contrasts for multiple comparisons. 1 Model 1 did not include any covariates; Model 2 adjusted for age, 
age2, height, and population group; and Model 3 adjusted for age, age2, height, population group, and 
total body fat and lean mass. 2 Two fewer spine scans available than hip scans at baseline; both were in 
the normoglycemic group. Number of hip scans given. Abbreviations: T2D = type 2 diabetes; BMC = 
bone mineral content; BA = bone area; aBMD = areal bone mineral density.  
 
 
 
 
 Normoglycemia Pre-diabetes T2D p-trend 1 
    Model 1 Model 2 Model 3 
Participants (n) 358 51 21    
Femoral neck       
   BMC (g) 5.29 ± 0.04ab 5.47 ± 0.12a 5.30 ± 0.19b 0.37 0.02 0.15 
   BA (cm2) 5.83 ± 0.02 5.87 ± 0.06 5.76 ± 0.09 0.52 0.86 0.85 
   aBMD (g/cm2) 0.908 ± 0.01ab 0.932 ± 0.02a 0.920 ± 0.03b 0.47 0.01 0.08 
Total hip       
   BMC (g) 47.96 ± 0.43 49.66 ± 1.14 48.41 ± 1.78 0.38 0.25 0.71 
   BA (cm2) 44.79 ± 0.24 44.85 ± 0.63 43.78 ± 0.99 0.60 0.52 0.33 
   aBMD (g/cm2) 1.069 ± 0.01ab 1.107 ± 0.02a 1.106 ± 0.03b 0.10 0.02 0.14 
Lumbar spine 2       
   BMC (g) 76.66 ± 0.76 77.72 ± 2.00 78.64 ± 3.11 0.75 0.53 0.55 
   BA (cm2) 70.27 ± 0.33 68.99 ± 0.88 69.54 ± 1.38 0.37 0.07 0.16 
   aBMD (g/cm2) 1.086 ± 0.01 1.124 ± 0.02 1.127 ± 0.03 0.13 0.21 0.42 
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Supplemental Table 3.1. Annual percent change in bone outcomes by glycemic status at baseline and follow-up. 
Values are unadjusted annual percent change from baseline in bone mineral status. Superscripts show means that were different based on model 2 using 
contrasts for multiple comparisons. 1 Model 1 did not include any covariates; Model 2 adjusted for age, age2, height, and population group; and Model 
3 adjusted for age, age2, height, population group, initial bone measures, baseline total body fat and lean mass, and annual percent change in total 
body fat and lean mass. 2 Five fewer spine scans available than hip scans at three-year; four in the normo/normoglycemic group and one in the 
pre/prediabetic group. Number of hip scans given. Abbreviations: T2D = type 2 diabetes; BMC = bone mineral content; BA = bone area; aBMD = 
areal bone mineral density.  
 
Baseline: Normoglycemia Pre-diabetes 
Normoglycemia 
or Pre-diabetes 
T2D p-Value 1 
Follow-Up: 
Normoglycemia 
 
Pre-diabetes 
 
Normoglycemia 
 
Pre-
diabetes 
 
T2D 
 
T2D 
 
 
Model 1 
 
Model 2 
 
Model 3 
Participants (n) 272 65 25 19 12 18    
Femoral neck          
     BMC -0.54 ± 0.10 -0.23 ± 0.20 -0.62 ± 0.32 0.23 ± 0.37 -0.66 ± 0.46 -0.49 ± 0.38 0.30 0.24 0.27 
     BA -0.15 ± 0.07 -0.04 ± 0.15 -0.51 ± 0.25 0.36 ± 0.28 0.31 ± 0.36 0.26 ± 0.29 0.11 0.11 0.09 
     aBMD -0.39 ± 0.07 -0.17 ± 0.14
ac -0.11 ± 0.23b -0.13 ± 0.27 -0.96 ± 0.33
bc -0.76 ± 0.27a 0.11 0.04 0.05 
Total hip          
    BMC -0.52 ± 0.08 -0.45 ± 0.16 -0.26 ± 0.26 0.18 ± 0.30 -0.61 ± 0.38 -0.06 ± 0.31 0.19 0.37 0.20 
    BA -0.40 ± 0.05 -0.48 ± 0.11 -0.11 ± 0.18 -0.13 ± 0.21 -0.45 ± 0.26 -0.22 ± 0.21 0.37 0.30 0.40 
    aBMD 0.12 ± 0.05 0.03 ± 0.10 -0.15 ± 0.17 0.31 ± 0.19 -0.17 ± 0.24 0.15 ± 0.20 0.18 0.39 0.27 
Lumbar spine2          
     BMC 0.34 ± 0.10 0.54 ± 0.21 0.40 ± 0.33 0.66 ± 0.39 1.56 ± 0.48 0.25 ± 0.39 0.22 0.42 0.50 
     BA -0.18 ± 0.06 -0.13 ± 0.12 -0.03 ± 0.19 0.03 ± 0.22 0.76 ± 0.27 -0.34 ± 0.22 0.03 0.06 0.15 
     aBMD 0.51 ± 0.08 0.67 ± 0.15 0.42 ± 0.25 0.62 ± 0.29 0.80 ± 0.36 0.59 ± 0.29 0.90 0.54 0.59 
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Men Aged 20-66 years 
(n=544) 
Excluded (n=114*) 
No glucose measures at baseline (n=12) 
No TB scan at baseline (n=23^) 
Study withdraw or no glucose at 36 months (n=79) 
(n=430) 
Normoglycemia 
Baseline analysis (n=358) 
 
Pre-diabetes  
Baseline analysis (n=51) 
 
T2D  
Baseline analysis n=21 
Remained normoglycemic (n=272)^# 
 
Progressed to pre-diabetes (n=65) 
 
Progressed to T2D (n=8)^ 
Remained pre-diabetic (n=19) # 
Reverted to normoglycemia (n=25) 
 
Converted to T2D (n=4) 
 
No DXA scans at follow-up (n=3)  
Follow-up analysis (n=18) 
 
No DXA scans at follow-up (n=13)  
Follow-up analysis (n=345) 
No DXA scans at follow-up (n=3)  
Follow-up analysis (n=48) 
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 Figure 3.1. Flowchart of participants included in the baseline and rate of change analyses.  * Individuals who were unable to 
be categorized into glycemic groups were excluded.  ^ Number of hip scans are shown, there were two fewer spine scans 
available than hip scans at baseline (both were in the normo/normoglycemic group).  #  Number of hip scans are shown, there 
were five fewer spine scans available than hip scans at three-year (four in the normo/normoglycemic group and one in the pre-
/pre-diabetes group). Abbreviations: DXA, dual-energy X-ray absorptiometry; T2D, type 2 diabetic.
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Figure 3.2. Marginal mean annual percent change in FN aBMD according to glycemic groups adjusted for age, age2, height, 
population group, and total body fat and lean mass. Means with similar letters are significantly different from each other. 
Abbreviations: FN = femoral neck; aBMD = areal bone mineral density; T2D = type 2 diabetes.  
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Figure 3.3. The relationship between baseline hip aBMD and lean mass varied by 
glycemic status (glycemic status-by-lean mass interaction, p = 0.004). Abbreviations: 
aBMD = areal bone mineral density; T2D = type 2 diabetes.  
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Abstract 
Objective: The transition from pre-diabetes to normoglycemia leads to improved plasma 
blood lipids, while conversion from normoglycemia and pre-diabetes to type 2 diabetes 
(T2D) results in worsening plasma blood lipids. The aim of the current study was to 
explore the associations of cross-sectional and longitudinal changes in glycemic status 
with baseline and changes in fasting blood lipids. 
Methods: Data from the South Dakota Rural Bone Health Study are used for the current 
analyses. Participants were 300 men, aged 20 to 66 years, who participated in the South 
Dakota Rural Bone Health Study and completed baseline assessments and 192 men who 
completed a 36-mo follow-up assessment and had fasting blood glucose and lipid, 
anthropometrics, body composition, and dietary intake. Pre-diabetes was defined by 
fasting plasma glucose 100 to 125 mg/dL, and T2D was determined by self-reported 
T2D, current use of the anti-diabetic drug (insulin/oral hypoglycemic agents), or a fasting 
serum glucose concentration (≥126 mg/dL) at baseline or follow-up. Multivariate 
analyses were used to estimate marginal means of baseline and change in plasma lipid 
outcomes among different categories of glycemic status controlling for covariates.  
Results: T2D, but not pre-diabetes, was positively associated with triglyceride (beta 
coefficient = 0.29, p = 0.003), cardio risk ratio (beta coefficient = 0.64, p = 0.01), and 
atherogenic index of plasma (beta coefficient = 0.10, p = 0.01), and negatively associated 
with low-density lipoprotein (beta coefficient = -13.92, p = 0.05). No significant 
association was observed between changes in glycemic status and changes in lipid 
profile. 
110 
 
Conclusion: T2D men had an atherogenic lipid profile and are at increased risk for 
cardiovascular disease.    
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Introduction 
Pre-diabetes and type 2 diabetes (T2D) are major public health challenges. The 
prevalence of prediabetes and T2D in US adults aged ≥ 20 years reported by the National 
Health and Nutrition Examination Survey has increased: pre-diabetes from 59.9% in 
1999-2004 to 78.5% in 2011-2014 [1] and T2D from 8.8% in 1999-2000 to 11.7 % in 
2013-2014 [2].  
Dyslipidemia, defined as having one or more of the following criteria: high-
density lipoprotein cholesterol (HDL-C) < 40 mg/dL, non-HDL-C ≥ 160 mg/dL, 
triglyceride (TG) ≥150 mg/dL, or self-reported taking lipid-lowering medications, is 
estimated to occur in 51.2% of adults with pre-diabetes [1] and 77.0% of adults with T2D 
[3]. The underlying mechanism for dyslipidemia in pre-diabetes and T2D is the presence 
of insulin resistance contributing to the diminished activity of lipoprotein lipase and 
elevated activity of hepatic TG lipase, which in turn increases TG concentrations and 
decreases HDL-C concentrations [4]. Despite abundant cross-sectional data on 
conventional lipid parameters in men with pre-diabetes and T2D, findings are 
inconclusive, with some cross-sectional studies reporting differences in total cholesterol 
(TC), HDL-C, low-density lipoprotein cholesterol (LDL-C), and TG among men with 
different glycemic status while other studies do not [5-9]. Recently, the cardiac risk ratio 
(CRR; TC/HDL-C) and the atherogenic index of plasma (AIP; log [TG/HDL-C]) have 
been introduced and used as atherogenic indices and reflect the balance between 
atherogenic lipids and antiatherogenic lipoproteins. Some studies have evaluated lipid 
ratios in pre-diabetes and T2D and revealed greater CRR and AIP in pre-diabetic and 
T2D individuals than in their normoglycemic counterparts [5,10,11], while other studies 
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have shown no difference in CRR and AIP between T2D and normoglycemic individuals 
[12,13].  
Inconsistent findings from previous cross-sectional studies suggest extending 
knowledge on the timing of the impact of glycemic status on lipid profile and ratios. Only 
two prospective randomized trials have examined changes in individual lipid measures in 
relation to changes in glycemic status over time. Conversion from pre-diabetes to T2D 
resulted in increased TC and TG and decreased HDL-C [14,15].  Two other trials found 
no change from baseline in CRR and AIP among adults with T2D who received placebo 
[12,16]. To the best of our knowledge, longitudinal observational studies have not been 
conducted to evaluate the impact of changes in glycemic status on changes in lipid 
measures and ratios over time. The aim of this study was to determine the effects of 
cross-sectional and longitudinal changes in glycemic status on baseline and changes in 
lipid biomarkers and CRR and AIP ratios.  
We hypothesized that 1) pre-diabetic and T2D men would have greater TC, LDL-C, 
TG, CRR, and AIP and lower HDL concentrations than normoglycemic men at baseline; 
2) TC, LDL-C, TG, RCC, and AIP concentrations would increase, and HDL 
concentrations would decrease, in normoglycemic men who developed pre-diabetes or 
T2D; and 3) TC, LDL-C,TG, CRR, and AIP concentrations would decrease, and HDL 
concentrations would increase, in pre-diabetic men who reverted to normoglycemia 
compared to prediabetic men who remained pre-diabetic.  
Methods 
Study population 
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The South Dakota Rural Bone Health Study (SDRBHS) is a population-based 
longitudinal study originally designed to study the effect of lifestyle factors on bone and 
body composition. The design and recruitment of the study participants have been 
previously published [17]. In brief, a total of 1,271 men and women aged 20 to 66 years 
from eight counties in eastern South Dakota were recruited to participate in the study. 
The current analysis is limited to 544 men, comprising 410 men who farmed at least 75% 
of their lives (rural) and 134 men who never lived on an active farm (non-rural). The 
rural population was divided into Hutterites and non-Hutterites. A Hutterite is an 
individual of Hutterite descent who lived on a Hutterite colony. Hutterites are an 
Anabaptist religious group who believes in isolated communal living and self-sufficiency 
through an agriculturally advanced lifestyle. Non-Hutterites were randomly selected from 
the eight-county region as described elsewhere [17].  
Among 544 men who completed the baseline visit between 2001 and 2004, 244 men 
were excluded at baseline for the following reasons: no blood glucose or fasting lipid 
concentrations (n=225), missing body composition measurements (n=11), use of lipid-
lowering medications (n=7), and no dietary intake data (n=1) (Figure 4.1). The follow-up 
visit occurred three years after the baseline visit. At follow-up we excluded men with no 
blood glucose or fasting lipid concentrations (n=67) or body composition (n=41) 
measurements at follow-up (Figure 4.1). After baseline and follow-up exclusions of 
participants, 300 and 192 men were included in the baseline and follow-up analyses, 
respectively. The study was approved by the South Dakota State University Institutional 
Review Board, and informed consent was obtained from all participants. 
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Assessment of pre-diabetes and T2D  
According to the American Diabetes Association (ADA) diagnostic criteria, 
individuals with a fasting blood glucose of 100 to 125 mg/dL were classified as having 
pre-diabetes [18]. T2D was determined by one of the following criteria: self-reported 
diabetes, current use of an anti-diabetic drug (insulin or oral hypoglycemic agents), or a 
fasting blood glucose concentration ≥126 mg/dL [18]. The same criteria for the diagnosis 
of pre-diabetes and T2D were applied at both the baseline and three-year visits. Glucose 
was measured at baseline and follow-up. Attempts were made to obtain fasting blood 
samples, and measurements were made in the field from a sample of venous whole blood 
(EDTA) using an Accu-Check Advantage glucometer (Roche Diagnostics, Indianapolis, 
IN).    
Measurement of plasma lipid  
Plasma samples were collected after an overnight fast for measurements of TC, HDL-
C, and TG. Blood samples were sent to the Clinical Laboratories of the Midwest (Sanford 
Health Systems, Sioux Falls, SD) for analyses. LDL-C was computed using the 
Friedewald formula for men with TG concentrations <400 mg/dL. Therefore, LDL-C was 
not calculated for men with TG concentrations >400 mg/dL (n=21 at baseline and n=14 
at follow-up visits). The coefficients of variation of TC, HDL-C, and TG were 1% [19].  
Lipid ratios were calculated as follows: CRR = TC/HDL-C [20] and AIP = log 
(TG/HDL-C) [11]. The normal ranges for CRR and AIP are <4 to 1 and -0.3 to 0.1, 
respectively [21,22]. 
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Assessment of covariates  
Interviewer-administered questionnaires were used to obtain information on 
demographics, medication use, medical history, and dietary intake. Information on the 
use of prescription medications and the presence of chronic diseases were collected at 
both visits. Participants were asked to report if they were currently taking cholesterol-
lowering drugs and any prescribed medications. If yes, they provided information about 
drugs. Dietary intake was assessed quarterly at both baseline and follow-up visits using 
24-hour dietary recalls. Trained interviewers administered 24-hour dietary recalls, and 
dietary recall data were analyzed for macronutrients using Nutritionist Pro software 
(version 2.3.1, 2004, First DataBank, Inc., San Bruno, CA). For foods not available in the 
Nutritionist Pro software, the nutrient composition of the foods was obtained from 
entering the recipes. Nutrient intakes at baseline were the averages of the baseline, 3- and 
6-month recalls and the measures at the three-year visit were the averages of the 30-, 33- 
and 36-month recalls.  
Body height and weight were measured in lightweight clothes without shoes using 
calibrated stadiometer and scale. Standing height was measured to the nearest 0.5 cm in 
duplicate with a Seca stadiometer (Chino, CA). A third measurement was taken if the 
discrepancy between the duplicate height measurements was more than 0.5 cm. Weight 
was measured to the nearest 0.1 kg with a Seca digital scale (Model 770, Chino, CA).  
  Body composition was assessed using dual-energy x-ray absorptiometry (DXA) 
(Discovery, Software Version 12.01, Hologic, Waltham, MA).  A total body scan was 
completed with boundaries for the various anatomical regions set according to 
manufacturer’s specifications. The step phantom scan for body composition calibration 
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was completed weekly as suggested by the manufacturer. Prior to DXA measurements, 
the Hologic Spine Phantom was completed for quality control.  All scans were analyzed 
by the same ISCD-certified technician. Scan results were deleted for obese participants 
with an equivalent epoxy thickness greater than 12 inches, as determined by the Hologic 
software, per manufacturer recommendations (n=16 men: n=7 Hutterite, n=4 rural, n=5 
non-rural).  DXA-derived measurements of the total body and trunk fat mass were 
determined from the whole-body scans. Percent of total body (TB) fat in the trunk was 
computed as trunk fat mass divided by total body fat mass times 100. Our coefficient of 
variation for total body fat in 15 adults (1 male) using triplicate scans with repositioning 
between each scan is <1.5%. 
Statistical analysis 
Analysis of variance and Fisher’s exact test for categorical variables were used to 
determine statistical significance in baseline characteristics. Characteristics were 
expressed as a mean ± standard error (SE) for variables with a normal distribution, 
geometric mean (95% confidence interval [CI]) for log-transformed variables (TG), and 
proportions of participants for categorical variables. Multiple regression models were 
used to estimate marginal means ± SE for baseline lipid indices and absolute changes in 
outcome measures by different categories of glycemic status. Differences in marginal and 
geometric means among glycemic groups were evaluated using post hoc contrast tests. 
We previously reported that demographic and anthropometric characteristics, as well as 
macronutrient intakes were cross-sectionally associated with lipid measures and ratios 
[19]; therefore, these previously identified covariates were included in the linear models. 
The baseline statistical model was adjusted for age, height, weight, percent of TB fat in 
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the trunk, percent of calories from carbohydrates, and percent of calories from fat. The 
longitudinal model was adjusted for the same variables included in the baseline model as 
well as absolute changes in weight, use of lipid-lowering medication at the three-year 
visit, and baseline measure of the specific blood lipid being modeled. Absolute changes 
in percent of TB fat in the trunk, percent of calories from carbohydrates, and percent of 
calories from fat were non-significant; hence, they were excluded from all longitudinal 
models. The assumptions of linearity, normality, and homoscedasticity were evaluated 
visually to ensure no violation of assumptions. The presence of collinearity was assessed 
using the variance inflation factor. All analyses were performed using JMP software 
(version 13, SAS Institute, Cary, NC) and the statistical significance level was set at p < 
0.05 (2-tailed). 
Results 
Baseline characteristics  
Of the 300 men at baseline, 59 (19.7%) and 17 (5.7%) had pre-diabetes and T2D, 
respectively. Overall, the mean (±SE) age was 40.3 ± 0.7 years, weight was 91.2 ± 0.9 
kg, BMI was 29.0 ± 0.3 kg/m2, and percent of TB fat in the trunk region was 50.3 ± 
0.4%. Pre-diabetic and T2D men were older and had greater body weight, BMI, and 
percent of TB fat in the trunk than normoglycemic men. Percent of calories from 
carbohydrates was higher among normoglycemic men compared to T2D men (Table 4.1).  
Baseline characteristics of men who completed the three-year follow-up visit are 
presented in Table 4.2. Among the 142 normoglycemic men at follow-up, 95 (66.9%) 
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remained normoglycemic, 44 (31%) became pre-diabetic, and 3 (2.1%) developed T2D. 
Of the 41 pre-diabetic men over a three-year period, 18 (43.9%) remained pre-diabetic, 
19 (46.3%) reverted to normoglycemia, and 4 (9.8%) converted to T2D. Normoglycemic 
men who remained normoglycemic throughout the study were younger and had lower 
body weight and BMI than men with pre-diabetes and T2D and normoglycemic or pre-
diabetic men who developed T2D.  
Cross-sectional analysis 
Table 4.3 presents both unadjusted and adjusted mean lipid measures and ratios 
according to the glycemic status at baseline. Unadjusted TC concentrations were higher 
in the T2D group than in the normoglycemic group, but differences disappeared after 
adjustment for covariates. The unadjusted mean of LDL-C concentrations did not vary 
among the glycemic groups, but it was higher in the normoglycemic group than in the 
T2D group after adjusting for age, height, weight, percent of TB fat in the trunk, percent 
of calories from carbohydrates, and percent of calories from fat. This may be explained in 
part by a higher percent of men with T2D have TG>400 mg/dl and thus no LDL-C 
measurements (see Table 4.3 footnote).  HDL-C concentrations were similar among 
glycemic groups in both unadjusted and adjusted models.  TG, CRR, and AIP were lower 
in the normoglycemic men compared to men with T2D (both unadjusted or adjusted 
models). 
Longitudinal analysis 
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Table 4.4 presents unadjusted and adjusted mean changes in lipid biomarkers and 
ratios according to the baseline glycemic status and changes in glycemic status during the 
follow-up period. Unadjusted analyses revealed significant changes in TC and LDL-C 
concentrations across various categories of glycemic status at follow-up, but after 
adjusting for covariates there were no differences among categories in changes in TC and 
LDL-C (Table 4.4).  Additionally, there were no differences among categories of 
glycemic status either before or after adjusting for covariates in TG, CRR or AIG.  
Results did not differ if 24 participants who were taking cholesterol-lowering 
medications at the three-year visit were excluded.  
Discussion 
With respect to the first hypothesis, pre-diabetic men had similar plasma blood 
lipids as normoglycemic men. T2D men had greater TG, CRR, and AIP and lower LDL-
C concentrations compared to their normoglycemic counterparts, but there were no 
differences in TC and HDL-C concentrations. This is the first observational longitudinal 
study to evaluate the association of changes in glycemic status with changes in plasma 
blood lipids. Changes in glycemic status were not observed to be associated with changes 
in lipid profiles over a three-year period once covariates were included in the analyses.    
In contrast to earlier findings [5,23-26], prediabetes, as defined in our study, was 
not associated with the lipid profiles that differed from normoglycemic men. There is a 
possible explanation for this result. Fasting blood glucose in our study is at the lower end 
of the pre-diabetes threshold.  Some investigators have reported an association between 
impaired fasting glucose and increased TC, TG, and LDL-C concentrations [5,23], while 
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impaired glucose tolerance is associated with a more atherogenic lipid profile 
(hypertriglyceridemia, increased small dense LDL, and low  HDL-C) [5,23,24,27]. This 
can be explained by different pathophysiology between impaired fasting glucose and 
impaired glucose tolerance. Patients with impaired fasting glucose have insulin resistance 
in the liver and normal insulin sensitivity in the muscle, whereas patients with impaired 
glucose tolerance have insulin resistance in the skeletal muscle and milder insulin 
resistance in the liver [28]. In the presence of impaired fasting glucose, very low-density 
lipoprotein (VLDL) is elevated as a result of increased hepatic TG lipoprotein synthesis. 
This leads to increased production and secretion of hepatic apo B-100 resulting in 
hypertriglyceridemia [4]. Hyperinsulinemia promotes free fatty acid flux to the liver by 
suppressing liver adipocyte lipolysis resulting in an increase in hepatic secretion of 
VLDL leading to hypertriglyceridemia. In addition, a decrease in lipoprotein lipase 
activity of adipose tissue contributes to reduce VLDL breakdown and elevations in TG 
concentrations [4].  
In the state of impaired glucose tolerance, impaired fatty acid uptake and 
oxidation in skeletal muscle leads to the accumulation of free fatty acids and lipids that 
promote hepatic synthesis and secretion of TG-enriched VLDL particles. These particles 
are exchanged for TG-enriched LDL and HDL particles by cholesterol ester transfer 
protein [29,30]. Hepatic TG lipase hydrolyzes TG-enriched LDL and HDL particles and 
accelerates clearance of LDL and HDL particles resulting in an increase in small dense 
LDL particles and a decrease in concentration of HDL-C [30]. Our results agree with 
previous cross-sectional studies that have reported a positive association between T2D 
and TG, CRR, and AIP [5,11,25].  
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In contrast with the two previous clinical studies, the current study found that 
changes in lipid profile among men who became pre-diabetic or T2D did not differ from 
those who remained pre-diabetic and normoglycemic during the follow-up period. 
Goldberg et al. [15] reported that TG concentration increased, and HDL-C concentration 
decreased in middle-aged adults who progressed to pre-diabetes over a one-year follow-
up. They also reported that reversion from pre-diabetes to normoglycemia was associated 
with increases in HDL-C and LDL-C concentrations and decreases in TG concentration 
[15], suggesting that regression from pre-diabetes to normoglycemia may lead to reduced 
cardiovascular risk.  Reductions in HDL-C and LDL-C concentrations and increases in 
TC and TG concentrations were observed in pre-diabetic adults who converted to T2D 
[14,15]. Findings from our study are consistent with a previous study that reported no 
changes in TC, HDL-C, and TG concentrations among pre-diabetic men who reverted to 
normoglycemia or remained pre-diabetic throughout the study [14].  
Study population and design, as well as methodological limitations, may 
contribute to contradictory findings regarding the effects of changes in glycemic status on 
changes in blood lipid levels. We enrolled men with a wide age range (20 to 66 years) in 
comparison to clinical trials that included only middle-aged and older adults. Our 
diagnosis of pre-diabetes and T2D was based on fasting plasma glucose, a previous 
diagnosis of diabetes, or current prescribed diabetic medications, while the clinical trials 
used a combination of fasting plasma glucose and oral glucose tolerance tests to confirm 
the diagnosis of pre-diabetes and T2D. 
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Our study has some limitations. The major limitation of this study is the small 
number of T2D cases at follow-up. There were only seven men who developed T2D and 
nine men who were T2D throughout the study. The sample size needed to reach 5% 
significance with 80% power at the difference currently observed is 21 in the 2TD group. 
Study participants were predominantly white men; therefore, the results cannot be 
generalized to other races or women. With a small sample size and including only men in 
the study, caution must be applied, as the findings need to be confirmed by future studies.  
The present study has several strengths. The SDRBHS is a population-based, 
longitudinal study and fasting blood glucose and lipids were measured at baseline and 
follow-up visits which enabled us to examine the association of changes in glycemic 
status with changes in lipid profile over a three-year period. To the best of our 
knowledge, this is the first population-based study with diverse lifestyles addressing 
changes in lipid measures across various categories of abnormal glycemic status at 
follow-up. Dietary recalls were administered quarterly and the average of three recalls at 
baseline (baseline, 3- and 6-month) and follow-up (30-, 33- and 36-month) was used to 
estimate nutrient intake.  
Conclusion 
In conclusion, we found that no differences in plasma blood lipids were noted 
between pre-diabetes and normoglycemia. T2D men had lower LDL-C and greater TG, 
CRR, and AIP than normoglycemic men. Changes in glycemic status were not associated 
with changes in lipid profile before or after excluding participants taking lipid-lowering 
therapy from analyses. The findings of this study indicate that T2D men had a more 
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atherogenic lipid profile than their normoglycemic counterparts. The current study 
contributes to existing knowledge of glycemic effect on lipid profile. Large longitudinal 
studies could provide more definitive evidence on change in glycemic status in relation to 
changes in blood lipids.      
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Table 4.1. Baseline characteristics of men by glycemic status at baseline. 
 Normoglycemia Pre-diabetes T2D p-Value 
1 
Participants (n) 224 59 17  
Age (years) 38.0 ± 0.8ab 45.5 ± 1.6b 52.2 ± 2.9a <0.001 
Anthropometrics      
   Height (cm) 177.5 ± 0.4 177.5 ± 0.8 175.7 ± 1.5 0.53 
   Weight (kg) 89.2 ± 1.0ab 96.9 ± 1.9b 99.0 ± 3.6a <0.001 
   BMI (kg/m2) 28.3 ± 0.3ab 30.8 ± 0.5b 32.0 ± 1.1a  <0.001 
Body composition      
   %TB fat in trunk 49.1 ± 0.4ab 53.1 ± 0.8b 56.9 ± 1.6a <0.001 
Dietary intake      
   % kcal CHO 42 ± 1a 40 ± 1 37 ± 2a 0.01 
   % kcal fat 39 ± 0 40 ± 1 41 ± 2 0.26 
Fasting glucose 
(mg/dL) 
86.0 ± 1.1ab 
(54-99) 
107.3 ± 2.1b 
(100-125) 
160.5 ± 3.9a 
(82-310) 
<0.001 
Data are presented as unadjusted mean ± SE (range).1 P value is based on ANOVA using a post hoc Tukey 
test for multiple comparisons. Means with similar superscripts are different. Abbreviations: T2D, type 2 
diabetes; TB, total body; %kcal CHO, percent of calories from carbohydrates; %kcal fat, percent of calories 
from fat.  
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Table 4.2. Baseline characteristics of men completing a three-year follow-up by glycemic status at baseline and follow-up. 
Baseline: Normoglycemic Pre-diabetic 
Normoglycemic 
or Pre-diabetic 
T2D  
Follow-Up: Normoglycemic Pre-diabetic Normoglycemic Pre-diabetic T2D T2D p-Value 
1 
Participants (n) 95 44 19 18 7 9  
Age (years) 35.9 ± 1.2abc 41.1 ± 1.7d 43.7 ± 2.6 46.8 ± 2.7a 52.1 ± 4.3b 53.1 ± 3.8cd <0.001 
Anthropometric measures        
    Height (cm) 177.4 ± 0.6 177.0 ± 0.9 178.2 ± 1.4 176.5 ± 1.4 172.9 ± 2.3 177.2 ± 2.0 0.49 
    Weight (kg) 87.3 ± 1.3abc 90.2 ± 2.0 94.2 ± 3.0 97.1 ± 3.1a 104.3 ± 4.9b 100.4 ± 4.3c <0.002 
     BMI 27.8 ± 0.4abc 28.8 ± 0.6d 29.7 ± 0.9e 31.2 ± 0.9a 34.8 ± 1.5bde 32.0 ± 1.3c <0.001 
Body composition        
  %TB fat in trunk 48.5 ± 0.7ab 51.3 ± 1.0 52.0 ± 1.5 55.5 ± 1.5a 51.6 ± 2.4 57.9 ± 2.1b <0.001 
Daily intake        
    % kcal CHO 42 ± 1 42 ± 1 40 ± 2 39 ± 2 39 ± 3 38 ± 3 0.30 
    % kcal fat 38 ± 1 39 ± 1 41 ± 1 40 ± 1 40 ± 2 40 ± 2 0.39 
% Cholesterol-lowering drug2 11.6 9.1 0.0 5.6 42.9 55.6 0.001 
Fasting glucose (mg/dL) 86.0 ± 1.6a 
(65-99) 
86.7 ± 2.4bc 
(54-99) 
104.5 ± 3.6c 
(100-114) 
108.8 ± 3.7b 
(101-123) 
98.6 ± 5.9 
(79-112) 
158.6 ± 5.2a 
(82-310) 
<0.001 
Data are presented as an unadjusted mean ± SE (range). 1 P value is based on ANOVA using a post hoc Tukey test for multiple comparisons and 
Fisher’s exact test for categorical variables. Means with similar superscripts are different.2 The percentage of men (n=24) who were taking cholesterol-
lowering treatment during a follow-up period of three years. Abbreviations: T2D, type 2 diabetes; TB, total body; %kcal CHO, percent of calories from 
carbohydrates; %kcal fat, percent of calories from fat.  
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Table 4.3. Mean of baseline plasma lipid biomarkers and ratios by glycemic status in 
men.  
 
Data are presented as mean ± SE. 1 P value was from linear regression models. The crude model was 
unadjusted for covariates. The adjusted model included age, height, weight, %kcal CHO, %kcal fat, and 
%TB fat in trunk. 2  LDL-C was not calculated for men with TG ≥ 400 mg/dL (n=21): 6.3%, 5.1% and 
23.5% of normoglycemic, pre-diabetic, and T2D men had TG > 400 mg/dl, respectively (p=0.05). 3  TG 
was log transformed for analysis, but it is presented in the table in the non-transformed form.  
4  Excluding three participants with TG ≥1573 mg/dL from the analysis resulted in for group differences 
(unadjusted P<0.001 and adjusted P=0.04).  The mean TG concentration was 161.7 ± 7.8 for 
normoglycemic group, 163.5 ± 15.2 for pre-diabetic group, and 251.3 ± 29.5 for T2D group.  
Abbreviations: T2D, type 2 diabetes; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; 
HDL-C, high density lipoprotein cholesterol; TG, triglyceride, CRR, cardio risk ratio (TC/HDL-C); AIP, 
atherogenic index of plasma (log (TG/HDL-C)). 
 
   
 Normoglycemia Pre-diabetes T2D p-Value 1 
Participants (n) 224 59 17  
Lipid profile (mg/dL)     
   TC     
      Crude 191.5 ± 3.1a 193.7 ± 6.1 222.8 ± 11.3a 0.03 
      Adjusted 194.4 ± 3.1 186.6 ± 6.1 206.7 ± 11.5 0.23 
   LDL-C2     
      Crude 116.3 ± 2.6 115.9 ± 5.1 108.7 ± 10.5 0.78 
      Adjusted 118.6 ± 2.5a  110.7 ± 5.0 93.8 ± 10.5a 0.05 
   HDL-C     
       Crude 44.6 ± 0.8 43.2 ± 1.5 38.8 ± 2.8 0.12 
       Adjusted 44.1 ± 0.7 44.5 ± 1.4 40.8 ± 2.7 0.45 
   TG34     
         Crude 169.7 ± 15.1a 181.8 ± 29.3 415.4 ± 54.6a <0.001 
         Adjusted 180.2 ± 14.2a 156.9 ± 28.0 363.0 ± 52.7a 0.01 
Lipid ratios      
   CRR      
         Crude 4.6 ± 0.1a 4.7 ± 0.2 6.1 ± 0.4a 0.001 
         Adjusted 4.7 ± 0.1a 4.4 ± 0.2 5.5 ± 0.4a 0.03 
    AIP      
          Crude 1.3a 1.4 1.6a <0.001 
           Adjusted 1.3a 1.3 1.5a 0.02 
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Table 4.4. Mean changes in plasma lipid biomarkers and ratios by change in glycemic status.  
Baseline: Normoglycemic Pre-diabetic Normoglycemic 
or Pre-diabetic 
T2D  
Follow-Up: Normoglycemic Pre-diabetic Normoglycemic Pre-diabetic T2D T2D p-Value 
1 
Participants (n) 95 44 19 18 7 9  
Lipid profile (mg/dL)        
  TC        
    Crude baseline  192.5 ± 4.8 190.5 ± 7.0 190.5 ± 10.7 193.0 ± 10.9 233.4 ± 17.6 207.6 ± 15.5 0.29 
    Crude change -1.8 ± 3.5a -3.3 ± 5.2 3.7 ± 7.9 -1.2 ± 8.1 -24.0 ± 13.0 -40.6 ± 11.4a 0.02 
    Adjusted change -17.9 ± 3.9 -22.1 ± 4.9 -16.8 ± 7.2 -21.2 ± 7.3 -12.3 ± 11.3 -35.4 ± 9.4 0.55 
  LDL-C§        
    Crude baseline 116.4 ± 4.4 116.9 ± 6.3 111.2 ± 9.6 115.2 ± 9.6 152.5 ± 16.6 111.0 ± 15.3 0.40 
    Crude change 1.2 ± 3.2a -2.1 ± 4.6 11.5 ± 7.0b -0.4 ± 7.0 -22.5 ± 12.2b -26.0 ± 11.3a 0.04 
    Adjusted change -14.5 ± 4.2 -21.5 ± 5.2 -12.3 ± 7.1 -21.3 ± 7.0 -16.4 ± 11.4 -29.1 ± 9.9 0.50 
  HDL-C        
    Crude baseline   43.4 ± 1.1 42.8 ± 1.7 41.9 ± 2.6 44.7 ± 2.6 40.9 ± 4.2 39.4 ± 3.7 0.86 
    Crude change 2.1 ± 0.9 0.8 ± 1.3 -0.2 ± 2.1 -0.7 ± 2.1 3.4 ± 3.4 3.7 ± 3.0 0.65 
    Adjusted change 1.2 ± 1.1 0.1 ± 1.5 -1.9 ± 2.2 -0.9 ± 2.2 2.5 ± 3.4 3.6 ± 2.9 0.54 
  TG¶        
    Crude baseline 168.8 ± 22.4 218.0 ± 32.9 200.6 ± 50.1 165.7 ± 51.5 213.7 ± 82.5 297.1 ± 72.8 0.08 
    Crude baseline‡ 160.6 ± 12.3a 140.8 ± 18.4b 200.6 ± 27.4 165.7 ± 28.2b 213.7 ± 45.2 297.1 ± 39.8a 0.008 
    Crude change* -17.9 ± 20.0 -51.0 ± 29.4 -57.6 ± 44.7 -0.3 ± 45.9 -50.7 ± 73.6 -123.0 ± 64.9 0.52 
    Adjusted change*  -6.8 ± 17.3 -5.1 ± 22.8 -7.3 ± 32.8 -1.2 ± 33.2 -8.8 ± 51.3 -67.7 ± 43.0 0.79 
Lipid ratios        
  CRR        
    Crude baseline 4.7 ± 0.2 4.7 ± 0.2 4.8 ± 0.4 4.5 ± 0.4 5.7 ± 0.6 5.6 ± 0.5 0.41 
    Crude change -0.3 ± 0.1 -0.2 ± 0.2 -0.1 ± 0.3 0.1 ± 0.3 -1.0 ± 0.5 -1.6 ± 0.5 0.06 
    Adjusted change -0.4 ± 0.2 -0.5 ± 0.2 -0.2 ± 0.3 -0.4 ± 0.3 -0.4 ± 0.5 -1.4 ± 0.4 0.21 
  AIP        
    Crude baseline 1.3 ± 0.03 1.3 ± 0.04 1.4 ± 0.06 1.3 ± 0.06 1.4 ± 0.09 1.5 ± 0.08 0.20 
    Crude change -0.05 ± 0.02 -0.02 ± 0.03 -0.09 ± 0.05 -0.02 ± 0.05 -0.08 ± 0.08 -0.14 ± 0.07 0.57 
    Adjusted change -0.05 ± 0.02 -0.01 ± 0.03 -0.02 ± 0.04 -0.02 ± 0.05 -0.001 ± 0.07 -0.08 ± 0.06 0.82 
Data are presented as mean ± SE. 
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†  P values for crude mean at baseline and in change using ANOVA with no covariates. P values for adjusted change were from linear regression models 
adjusting for age, height, weight, percent of calories from carbohydrates, percent of calories from fat, percent of TB fat in the trunk, use of 
cholesterol-lowering drug at 36-month (yes/no), change in body weight, and baseline measure of the specific blood lipid being modeled. 
§  LDL-C was not calculated for men with TG ≥ 400 mg/dL (n=16). 
¶  TG was log transformed for analysis, but it is presented in the table in the non-transformed form. 
‡  Excluding three participants (one normoglycemia/normoglycemia and two normoglycemia/pre-diabetes) with TG ≥936 mg/dL from the analysis 
resulted in group differences.   
*  Excluding one participant (one normoglycemia/normoglycemia) with ≥936 mg/dL from the analysis did not alter the conclusions. 
Abbreviations: T2D, type 2 diabetes; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; 
TG, triglyceride; CRR, cardio risk ratio (TC/HDL-C); AIP, atherogenic index of plasma (log (TG/HDL-C)).   
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Figure 4.1. Flowchart of participants. Abbreviations: T2D, type 2 diabetes.
Men Aged 20-66 years 
(n=544) 
Excluded at baseline (n=244): 
No glucose or fasting lipid profile (n=225) 
No body composition (n=11) 
Taking lipid-lowering medication (n=7) 
No dietary intake (n=1) 
Baseline analysis (n=300) 
Normoglycemia (n=224)  Pre-diabetes (n=59)  
 
T2D (n=17)  
Excluded at follow-up (n=82): 
No glucose or fasting lipids (n=55) 
No body composition (n=27) 
Excluded at follow-up (n=18): 
No glucose or fasting lipids (n=8) 
No body composition (n=10) 
Excluded at follow-up (n=8): 
No glucose or fasting lipids (n=4) 
No body composition (n=4) 
Remained normoglycemic (n=95) 
 
Progressed to pre-diabetes (n=44) 
Progressed to T2D (n=3) 
Remained pre-diabetic (n=18) 
 
Reverted to normoglycemia (n=19) 
 
Progressed to T2D (n=4) 
Included at follow-up analysis (n=9) Included at follow-up analysis (n=142) Included at follow-up analysis (n=41) 
130 
 
References  
1. Ali, M.K.; Bullard, K.M.; Saydah, S.; Imperatore, G.; Gregg, E.W. 
Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from 
serial cross-sectional surveys, 1988–2014. Lancet Diabetes Endocrinol 2018, 6, 
392-403. 
2. Caspard, H.; Jabbour, S.; Hammar, N.; Fenici, P.; Sheehan, J.J.; Kosiborod, M. 
Recent trends in the prevalence of type 2 diabetes and the association with 
abdominal obesity lead to growing health disparities in the USA: an analysis of 
the NHANES surveys from 1999 to 2014. Diabetes Obes Metab 2018, 20, 667-
671. 
3. Lin, P.-J.; Kent, D.M.; Winn, A.; Cohen, J.T.; Neumann, P.J. Multiple chronic 
conditions in type 2 diabetes mellitus: prevalence and consequences. Am J Manag 
Care 2015, 21, e23-34. 
4. Garg, A. Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care 
1996, 19, 387-389. 
5. Zhang, L.; Qiao, Q.; Tuomilehto, J.; Hammar, N.; Alberti, K.; Eliasson, M.; 
Heine, R.; Stehouwer, C.; Ruotolo, G.; Group, D.S. Blood lipid levels in relation 
to glucose status in European men and women without a prior history of diabetes: 
the DECODE Study. Diabetes Res Clin Pract 2008, 82, 364-377. 
6. Group, U.P.D.S. UK Prospective Diabetes Study 27: plasma lipids and 
lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997, 20, 
1683-1687. 
131 
 
7. Sosenko, J.; Kato, M.; Soto, R.; Goldberg, R. Plasma lipid levels at diagnosis in 
type 2 diabetic patients. Diabet Med 1993, 10, 814-819. 
8. Laakso, M.; Barrett-Connor, E. Asymptomatic hyperglycemia is associated with 
lipid and lipoprotein changes favoring atherosclerosis. Arteriosclerosis 1989, 9, 
665-672. 
9. Falko, J.M.; Parr, J.H.; Simpson, R.N.; Wynn, V. Lipoprotein analyses in varying 
degrees of glucose tolerance: comparison between non-insulin-dependent 
diabetic, impaired glucose tolerant, and control populations. Am J Med 1987, 83, 
641-647. 
10. Andreozzi, F.; Mannino, G.C.; Perticone, M.; Perticone, F.; Sesti, G. Elevated 1-h 
post-load plasma glucose levels in subjects with normal glucose tolerance are 
associated with a pro-atherogenic lipid profile. Atherosclerosis 2017, 256, 15-20. 
11. Dobiás̆ová, M.; Frohlich, J. The plasma parameter log (TG/HDL-C) as an 
atherogenic index: correlation with lipoprotein particle size and esterification rate 
inapob-lipoprotein-depleted plasma (FERHDL). Clin Biochem 2001, 34, 583-588. 
12. Tan, M.H.; Johns, D.; Glazer, N.B. Pioglitazone reduces atherogenic index of 
plasma in patients with type 2 diabetes. Clin Chem 2004, 50, 1184-1188. 
13. Yan, Z.; Liu, Y.; Huang, H. Association of glycosylated hemoglobin level with 
lipid ratio and individual lipids in type 2 diabetic patients. Asian Pac J Trop Med 
2012, 5, 469-471. 
132 
 
14. Nanditha, A.; Ram, J.; Snehalatha, C.; Selvam, S.; Priscilla, S.; Shetty, A.S.; 
Arun, R.; Godsland, I.F.; Johnston, D.G.; Ramachandran, A. Early improvement 
predicts reduced risk of incident diabetes and improved cardiovascular risk in 
prediabetic Asian Indian men participating in a 2-year lifestyle intervention 
program. Diabetes Care 2014, 37, 3009-3015. 
15. Goldberg, R.B.; Temprosa, M.; Haffner, S.; Orchard, T.J.; Ratner, R.E.; Fowler, 
S.E.; Mather, K.; Marcovina, S.; Saudek, C.; Matulik, M.J. The effect of 
progression from impaired glucose tolerance to diabetes on cardiovascular risk 
factors and its amelioration by lifestyle and metformin intervention: The Diabetes 
Prevention Program Randomized Trial. Diabetes Care 2009, 32, 726-732. 
16. Geohas, J.; Daly, A.; Juturu, V.; Finch, M.; Komorowski, J.R. Chromium 
picolinate and biotin combination reduces atherogenic index of plasma in patients 
with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized 
clinical trial. Am J Med Sci 2007, 333, 145-153. 
17. Specker, B.; Binkley, T.; Fahrenwald, N. Rural versus nonrural differences in 
BMC, volumetric BMD, and bone size: A population-based cross-sectional study. 
Bone 2004, 35, 1389-1398. 
18. American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. 
In standards of medical care in diabetes—2015. Diabetes Care 2015, 38, S8–S16. 
19. Niederauer, C.; Binkley, T.; Specker, B. Effect of truncal adiposity on plasma 
lipid and lipoprotein concentrations. J Nutr Health Aging 2006, 10, 154-160. 
133 
 
20. Bafna, A.; Maheshwari, R.; Ved, R.; Sarkar, P.; Batham, A. Study of atherogenic 
indices in nephrotic syndrome. Int J Biol Med Res 2012, 3, 2257-2260. 
21. Castelli, W.P. Cardiovascular disease: pathogenesis, epidemiology, and risk 
among users of oral contraceptives who smoke. Am J Obstet Gynecol 1999, 180, 
S349-S356. 
22. Dobiásová, M. AIP--atherogenic index of plasma as a significant predictor of 
cardiovascular risk: from research to practice. Vnitr Lek 2006, 52, 64-71. 
23. Zhang, L.; Qiao, Q.; Tuomilehto, J.; Hammar, N.; Janus, E.; Söderberg, S.; 
Mohan, V.; Ramachandran, A.; Dong, Y.; Lam, T. Blood lipid levels in relation to 
glucose status in seven populations of Asian origin without a prior history of 
diabetes: the DECODA study. Diabetes Metab Res Rev 2009, 25, 549-557. 
24. Lorenzo, C.; Hartnett, S.; Hanley, A.J.; Rewers, M.J.; Wagenknecht, L.E.; Karter, 
A.J.; Haffner, S.M. Impaired fasting glucose and impaired glucose tolerance have 
distinct lipoprotein and apolipoprotein changes: the insulin resistance 
atherosclerosis study. J Clin Endocrinol Metab 2013, 98, 1622-1630. 
25. Chakarova, N.; Tankova, T.; Atanassova, I.; Dakovska, L. Serum lipid and hsCRP 
levels in prediabetes–impaired fasting glucose (IFG) and impaired glucose 
tolerance (IGT). Diabetes Res Clin Pract 2009, 86, 56-60. 
26. Qian, Y.; Lin, Y.; Zhang, T.; Bai, J.; Chen, F.; Zhang, Y.; Luo, S.; Shen, H. The 
characteristics of impaired fasting glucose associated with obesity and 
dyslipidaemia in a Chinese population. BMC Public Health 2010, 10, 139, doi: 
10.1186/1471-2458-10-139. 
134 
 
27. Meigs, J.B.; Nathan, D.M.; Wilson, P.W.; Cupples, L.A.; Singer, D.E. Metabolic 
risk factors worsen continuously across the spectrum of nondiabetic glucose 
tolerance: the Framingham Offspring Study. Ann Intern Med 1998, 128, 524-533. 
28. Abdul-Ghani, M.A.; Tripathy, D.; DeFronzo, R.A. Contributions of β-cell 
dysfunction and insulin resistance to the pathogenesis of impaired glucose 
tolerance and impaired fasting glucose. Diabetes Care 2006, 29, 1130-1139. 
29. Corpeleijn, E.; Mensink, M.; Kooi, M.E.; Roekaerts, P.M.; Saris, W.H.; Blaak, 
E.E. Impaired skeletal muscle substrate oxidation in glucose‐intolerant men 
improves after weight loss. Obesity 2008, 16, 1025-1032. 
30. Kwiterovich Jr, P.O. The metabolic pathways of high-density lipoprotein, low-
density lipoprotein, and triglycerides: a current review. Am J Cardiol 2000, 86, 5-
10. 
 
 
 
 
 
  
135 
 
CHAPTER 5: Discussion and Overall Conclusions 
In this dissertation, we aimed to investigate the associations of baseline and 
changes in glycemic status with baseline and changes in body composition, bone health, 
and lipid profile in men aged 20 to 66 years from South Dakota Rural Bone Health Study. 
Chapter one introduces readers to the epidemiology and pathophysiology of pre-diabetes 
and type 2 diabetes as well as the effect of baseline glycemic status on baseline and 
changes in total and regional body composition, bone mass at FN, hip, and spine (aBMD, 
BMC, and bone area), and lipid profile.  
Chapter two studied the associations of baseline and changes in glycemic status 
with baseline and changes in body composition over a three-year follow-up. Our findings 
suggest that cross-sectional associations indicated that no differences in total and regional 
body composition were observed among glycemic groups. Changes in glycemic status 
were associated with changes in TB FM and LM and appendicular LM. Conversion from 
normoglycemia to pre-diabetes was associated with loss of TB and appendicular LM. 
Progression from normoglycemia or pre-diabetes to type 2 diabetes correlated with 
greater losses of TB and appendicular LM. Type 2 diabetes had effects on greater losses 
of TB and appendicular LM and greater gains in TB FM over a three-three period.  
In Chapter three, we focused on the effects of baseline and changes in glycemic 
status on baseline and changes in bone mass. The impact of baseline glycemic status on 
aBMD and BMC at multiple skeletal sites was not significant after adjustment for body 
composition differences. Associations of hip aBMD and BMC and spine aBMD with LM 
was attenuated in pre-diabetic men as compared to normoglycemic and T2D men. The 
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transition from normoglycemia or pre-diabetes to T2D was associated with a greater loss 
of FN aBMD. T2D was also associated with a greater loss of FN aBMD.  
Chapter four investigated the associations of cross-sectional and longitudinal 
changes in glycemic status with baseline and changes in plasma blood lipids. Our results 
suggested that there was no association between lipid profile and pre-diabetes. T2D men 
had greater TG, CCR, and AIP than their normoglycemic counterparts. No significant 
association was observed between changes in glycemic status and changes in lipid 
profile. The main findings of this dissertation are that the changes in glycemic status over 
time have adverse effects on body composition and bone health. The changes in glycemic 
status should be further explored in relation to changes in blood lipid.  
In conclusion, these findings provide new insights regarding the associations of 
cross-sectional and longitudinal changes in glycemic status with baseline and changes in 
body composition, bone, and lipid profiles. These findings have important implications 
for understanding and preventing the consequences of changes in glycemic status on total 
and regional body composition and areal bone mineral density. Conversion to pre-
diabetes and T2D clearly show an accelerated decline in TB and appendicular LM and 
T2D is associated with a greater decline of TB LM and greater gain in TB FM. Measures 
of body composition in pre-diabetic and T2D patients should be added to standards of 
medical care in diabetes. The prevention of pre-diabetes and T2D can be achieved 
through lifestyle modifications (increased physical activity and intakes of fruit, vegetable, 
and fiber, limit fat content, and weight reduction). These lifestyle modifications also may 
improve body composition by reducing loss of LM.   
 
